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Cardiovascular diseases (CVDs), a group of disorders that affect the heart and blood vessels, 
are globally the leading cause of death. According to the World Health Organization,  
the number of people that will die annually from CVDs will increase from 17.3 million (2008) 
to 23.3 million in 2030 [1, 2]. Recently, several studies have identified an immune component 
as an important factor linking a distinct set of lifestyle elements that is involved in CVDs 
progression and that plays a significant role in the pathophysiology of CVDs [3].  
During the evolutionary process animals developed a highly complex system that maintains 
internal homeostasis. The immune system protects organisms against exogenous pathogens 
and enables repair of tissue damage caused by infection or trauma. This system can be divided 
into two strictly connected categories: innate and adaptive. The innate immune system, 
through a network of distinct pathogen recognition receptors (PRRs), recognizes pathogen-
associated molecular patterns (PAMPs) and creates the first line of defense [4]. Activation  
of the immune system leads through a distinct set of effector cells (e.g. macrophages, NK cells, 
dendritic cells) to an acute response which is nonspecific and limited to a number of irritants 
[5]. On the other hand, the adaptive immune system which consists of several subsets  
of T cells and B cells is far more diverse and refers to an antigen-specific immune response. 
Cytokines play a crucial role in regulating the immune response. These small proteins, 
expressed by different types of cells, can either stimulate proinflammatory responses  
(e.g. IL1β, IFNγ, TNFα) or suppress them (e.g. IL10, TGFβ). 
In spite of the immune system’s complexity in certain conditions, the inflammatory response 
may damage host tissue and participate in pathophysiology of the disease [6]. In some cases, 
e.g. sepsis, the acute and systemic immune response may cause multiple organ dysfunction 
[7]. In other diseases, loss of immunological tolerance to self-antigens, described as 
autoimmunity, plays an important role in progression of illness. This is a major health issue,  
as autoimmunity has been identified as a contributing factor of 80 different disorders that 
collectively impact 4-7% of the population in the United States [8]. Moreover, in many 
disorders that are related to CVDs, prolonged exposure to potentially toxic agents creates 
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damage-associated molecular patterns (DAMPs) that trigger chronic inflammation which 
affects progression of a disease [9].  
 
Chronic inflammation participates in the development of atherosclerosis, which is a leading 
cause of coronary artery disease (CAD) [10]. Pathomechanism of this disorder consists  
of endothelial dysfunction with leukocyte recruitment, de-differentiation of vascular smooth 
muscle cells and asymmetrical focal thickening of the vessel wall [11]. Over time, initial lesions 
may transform into fully developed atheroma characterized by the presence of different cell 
types and a lipid-rich core surrounded by a fibrotic cup (Fig. 1-1). 
 
 
Fig. 1-1. Involvement of inflammation in the plaque development. 1, In stress conditions, DAMPs and PAMPs 
are created. These ligands provoke innate immune responses in the arterial wall and increase the 
permeability of the blood vessels for lipoproteins. 2, Activation of the ECs leads to the expression of 
chemokines, cytokines which enhance adhesion and extravasation of the leukocytes (3). 4, Activated 
endothelial cells express macrophage colony-stimulating factor (CSF) and cause differentiation of the 
attracted monocytes into macrophages. Intimal macrophages can not only take-up oxLDL which transform 
them into foam cells but also express cytokines, matrix metalloproteinases (MMPs) and reactive oxygene 
species (ROS). 5, Other professional antigen-presenting cells, such as dendritic cells (DCs), can uptake 
lipoproteins and other DAMPs in order to present them on the cell surface for recognition by the T cells. 
Activated T cells produce inflammatory cytokines e.g. IFNγ or IL12. 6, Smooth muscle cells upon change their 
phenotype from contractile to synthetic and start to proliferate and produce inflammatory mediators.  
 
Atherosclerotic plaque can narrow the lumen of the vessel and cause ischemia of the 
surrounding tissue [12]. Furthermore, in certain conditions the plaque may rupture and 
release the content of the necrotic core which triggers blood clot formation in the vessel 
(thrombosis). A thrombus may cause stenosis of the vessel or can detach and become  
an embolus that can block the flow of blood distant from its point of origin [12].  
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In a healthy vessel the function of the endothelial cells (ECs) is to maintain vascular 
homeostasis by regulating blood flow and creating a semi-selective barrier between the lumen 
and surrounding tissue. At this stage the ECs exert anticoagulant, antiplatelet and fibrinolytic 
properties [13]. However, in stress conditions (e.g. dyslipidemia, hypertension or diabetes), 
DAMPs and PAMPs are created. These ligands provoke innate immune responses in the 
arterial wall and increase the permeability of the blood vessels for lipoproteins, such as for 
low-density lipoprotein (LDL) or its oxidized form called oxLDL. Indeed, it has been shown that 
activation of the ECs leads to the expression of adhesion molecules such as E-selectin and 
VCAM-1 which, together with CCL2 and CCL5 chemokines, begin to promote leukocyte 
adhesion and their recruitment to the vessel wall. Moreover, inhibition of these chemokines 
in hypercholesterolemic, atherosclerosis-susceptible apolipoprotein E-deficient mice leads to 
a 90% reduction in atherosclerosis [14-16]. Activated endothelial cells express the 
macrophage colony-stimulating factor and cause differentiation of the attracted monocytes 
into macrophages [17]. Intimal macrophages can take-up oxLDL that eventually transform 
them into foam cells. In this initial step an early lesion, called a fatty streak, consists  
of a subendothelial deposition of lipids, macrophage foam cells loaded with cholesterol and  
T cells [12]. Recent evidence indicates that not only the macrophages but also vascular 
smooth muscle cells (VSMCs) expressing scavenger receptors can uptake lipoproteins and thus 
significantly contribute to foam cell formation [18]. In addition, macrophages present at the 
lesion site play an important role in stimulation of the innate immune response. Endogenous 
danger ligands that accumulate during atherosclerotic plaque development activate the PRRs, 
including toll-like receptors (TLRs) or NOD-like receptors, thereby activating an inflammatory 
response [16]. Depending on the nature of the ligand, macrophages exhibit different 
phenotypes. Classically activated macrophages (called M1) are activated by ligands of TLR-like 
lipopolysaccharide (LPS) or cytokines, e.g. interferon (IFN)-γ. These macrophages are enriched 
in progressing plaques and express high levels of pro-inflammatory cytokines, including IL1β, 
IL12, and TNFα as well as reactive oxygen and nitrogen species which increase oxidative stress 
in the vessel [16, 19]. In contrast to M1, alternatively activated macrophages (called M2) 
secrete anti-inflammatory cytokines (e.g. IL10) and seem to play a protective role 
 in atherosclerosis [16, 20]. Not only macrophages but also other professional antigen-
presenting cells, such as dendritic cells (DCs), can uptake lipoproteins and other DAMPs  
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in order to present them on the cell surface for recognition by the T cells [21, 22]. Several 
subsets of T cells have been identified in atheroma [22, 23]. Among them the best 
characterized has been the role of TH1 cells which, upon activation, express IFNγ, enhance 
development of the atherosclerotic lesion and contribute to plaque rupture. IFNγ activates 
not only monocyte macrophages and DCs but also ECs and VSMCs to secrete cytokines and 
chemokines as well as a large amount of reactive oxygen species (ROS) and matrix 
metalloproteinases [24]. These findings have been confirmed in animal models of 
atherosclerosis where TH1-deficient mice had significantly reduced atherosclerotic lesion 
formation [25]. In contrast to TH1, Treg cells suppress the immune response, resolve 
inflammation in the plaque and thus have an atheroprotective role [24]. The role of the other 
two CD4+ lymphocytes, TH2 and TH17, remains unknown as there are some conflicting reports 
about their function in atherosclerosis [22]. Furthermore, recent studies pointed to the 
involvement of CD8+ T cells and B cells in atherosclerosis, however, here also their exact role is 
unknown [22, 24]. Taken together, numerous studies reveal the importance of inflammation 
in all stages of plaque development and allow to consider atherosclerosis as a chronic 
inflammatory disease.  
 
Another recently uncovered example of organ damage involving inflammation is hypertension 
[26]. Hypertension is defined as a chronic medical state with elevated blood pressure (systolic 
≥140 and/or diastolic ≥90). Although hypertension is a major risk factor for cardiovascular 
mortality and morbidity, etiology of this disease remains poorly understood [27, 28]. Besides 
atherosclerosis, recent studies point to the importance of innate and adaptive immunity in the 
progression of a pathological state caused by elevated blood pressure. Increased immune cell 
infiltration has been observed in different models of hypertension. Macrophage colony-
stimulating factor-deficient mice remain normotensive and develop less vascular remodeling 
and oxidative stress despite angiotensin (Ang) II or DOCA salt treatment [29, 30]. Ang II and 
DOCA salt-induced hypertension was ameliorated in T and B cell deficient mice [31]. 
Moreover, treatment with immunosuppressive drugs such as mycophenolate mofetil 
attenuates hypertensive organ damage and reduces renal and vascular immune cell 
infiltration [8]. Other studies have shown that inhibition of the proinflammatory cytokines, 
e.g. TNFα, IL6 or IL17, protects animals in an Ang II-induced model of hypertension [8].  
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Despite the large amount of data implicating inflammation in hypertension, the exact 
mechanism of immune activation is poorly understood. It is believed that elevated blood 
pressure may trigger activation of PRR by DAMPs and promotes an innate immune response. 
Upon DAMPs stimulation, ECs and VSMCs change their function and produce cytokines and 
chemokines that enhance extravasation. Activated immune cells produce cytokines and 
reactive oxygen species that exacerbate tissue damage. Additionally, important regulators of 
blood pressure, such as endothelin (ET)-1 or Ang II, induce an adaptive immune response 
either through activation of the DCs or directly by acting on the T cells, such as TH1 cells. 
Activated T cells produce inflammatory cytokines, e.g. IFNγ, thus enhancing low-grade 
inflammation which contributes to organ damage [31, 32] (Fig. 1-2). 
 
 
Fig. 1-2. Role of inflammation in hypertension and hypertensive end organ damage. Damage-
associated molecular patterns (DAMPs) activate vasculature and components of the immune 
system leading to accelerated blood pressure increase and organ damage. Additionally regulators 
of blood pressure, such as ET-1 or Ang II, induce an adaptive immune response through activation 
of the dendritic cells (DCs) or directly by acting on the T cells [26]. 
 
Many of these cytokines, PAMPs and DAMPs (activators of TLRs) have shown to trigger  
the JAK/STAT pathway which is one of the pivotal pathways that operates at the frontier 
of innate and adaptive immunity and orchestrates the immune response [33]. Activation of  
this pathway with IFNγ triggers a signal transduction cascade that modulates inflammation 
and as such has a prominent role in cardiovascular diseases. Although not completely 
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understood, the significance of the JAK/STAT pathway in chronic inflammatory processes has 
recently been recognized in immune cells [34]. Far less is known about the contribution of the 
JAK/STAT pathway in immunomodulatory functions of other non-immune cells [35, 36]. 
Considering the fact that non-immune cells such as ECs and vascular smooth muscle cells 
(VSMCs) are actively involved in the progression of inflammation, a better understanding  
of the processes behind a non-immune cells activation will have a substantial clinical benefit. 
 
IFNγ Signaling Pathway 
 
Interferons were discovered by Isaacs and Lindermann in the late 1950s and were initially 
considered as compounds that interfere with viral infection [37]. Later observations provided 
evidence for a more complex function of interferons, including anti-microbial responses, 
regulation of apoptosis, proliferation and regulation of leukocyte migration.  
According to their homology, interferons are subdivided into 3 categories. IFNγ is a sole 
member of the type II family. In contrast to the type I family, IFNγ is produced primarily by 
activated subsets of T cells and NK cells, and also NKT cells, macrophages and DCs [38-42]. 
Canonical activity of IFNγ is mediated through the JAK/STAT pathway (Fig. 1-3).  
Fig. 1-3. JAK/STAT pathway. Binding of IFNγ 
to its receptor triggers oligomerisation of the 
IFNGR1 and IFNGR2 receptor. Activated JAK 
kinases phosphorylate cytoplasmatic domains 
of the receptor, enabling association of the 
STAT1. STAT1 is phosphorylated and after 
dissociation forms a stable homodimer in a 
parallel conformational state that migrate to 
the nucleus and activates transcription by 
binding to the DNA motifs (e.g. GAS). 
Conformational change of the STAT1 exposes 
phosphorylated tyrosine residues and thus 
facilitates action of phosphatases such as 
TCP45. Dephosphorylated STAT1 migrates to 
the cytoplasm where it can be again activated 
by JAK kinases. Literature data indicates 
presence of some other posttranslational 
modifications such as acetylation (Ac), 
deacetylation (HDAC) and SUMOylation of 
STAT1. 
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Binding of IFNγ to its receptor triggers oligomerisation of the IFNGR1 and IFNGR2 receptor. 
These conformational changes bring pre-associated JAK1 and JAK2 kinases into close 
proximity and facilitate transphosphorylation. Activated JAK kinases phosphorylate 
cytoplasmatic domains of the receptor, which serve as docking sites for the signal transducer 
and activator of transcription (STAT1). 
STAT1 belongs to a family of transcription factors that consists of seven members with 
conserved structural similarity [43, 44] (Fig. 1-4). 
 
 
Fig. 1-4. Structure of the STAT proteins. The N-terminal domain (N) is mostly involved in dimer complex 
formation. The coiled coil domain (CC) facilitates an interaction with transcription factors other than STATs 
and is involved in nuclear translocation. The DNA binding domain (DNA) promotes binding of STAT to the 
enhancer element. The linking domain (LK) is necessary for the proper conformation of adjacent domains. 
SH2 domain mediates binding to the cognate receptor and takes part in the formation of active STAT dimer. 
Due to the phosphorylation, preserved tyrosine (Y) is exposed and mediates an interaction with the related 
SH2 domain of the partner STAT. The less conserved domain among STATs is the transcriptional activation 
domain (T) which recruits transcriptional machinery and regulates gene transcription.  
 
Receptor-bound STAT1 is phosphorylated and after dissociation creates a stable homodimer 
in a parallel conformational state that translocates to the nucleus and, by binding to the DNA 
motif, called an interferon-gamma-activated sequence (GAS), activates transcription [45, 46] 
(Fig. 1-3). Inactivation of STAT1-transcriptional activity is related to conformational change 
and subsequent dephosphorylation [47, 48]. STAT1 which dissociates from the DNA alters its 
conformation from a parallel into an antiparallel one. This modification exposes 
phosphorylated tyrosine residues and thus facilitates action of phosphatases such as TCP45. 
Dephosphorylated STAT1 migrates to the cytoplasm where it can be again activated by JAK 
kinases [49, 50]. There is some evidence indicating that in certain conditions the biological 
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activity of IFNγ can be mediated by proteins other than STAT1. However, due to strong affinity 
of the activated IFNGR1 receptor to STAT1, transcriptional responses to IFNγ are dominated 
by STAT1 [51]. Although tyrosine 701 phosphorylation is crucial for transcriptional activity of 
STAT1, other studies have indicated the importance of other modifications [52, 53]. It has 
been shown that serine 727 phosphorylation in the carboxy-terminal domain is necessary for 
full transcriptional activation of STAT1 [54, 55]. Additionally, other posttranslational 
modifications such as acetylation and SUMOylation of STAT1 also play a role in regulating its 
activity. However, in contrast to phosphorylation, these modifications seem to inhibit  
the transcriptional activity of STAT1 [56-60].  
Among the cardiovascular disorders, the role of IFNγ is best characterized in atherosclerosis 
[61]. Most research points to the proinflammatory role of cytokines manifested by 
involvement of IFNγ in the development and progression of atheroma; for example, IFNγ was 
found to be expressed in human lesions and in T cells cloned from human plaques [62]. It was 
shown that atheroma formation is markedly reduced in genetic knockouts of IFNγ [63-66]. 
Russell et al. showed that a monoclonal antibody to IFNγ strikingly inhibited formation of 
obstructive vascular lesions [67]. Furthermore, Tellides et el. showed that the 
immunomodulatory effect of IFNγ on media expansion was present in the absence  
of leukocytes, further proving critical role of IFNγ in atherogenesis and modelling of cell 
behavior and cell-cell interactions of all cell types existing in the vessel wall [68]. In addition,  
a number of research studies have indicated that IFNγ boosts macrophage and SMC foam cell 
formation and inhibits SMC proliferation [61, 69]. Interestingly, other reports suggested that 
IFNγ stimulates proliferation of VSMCs [70, 71]. The function of IFNγ in the pathology of 
atherosclerosis also includes activation and differentiation of T cells as well as stimulation  
of macrophages in order to express TNFα, IL6 and nitric oxide [61].  
 
Recent studies indicate this cytokine’s role in other CVDs. Most of the animal models suggest 
an important role of IFNγ in inflammatory cell recruitment, cytokine and chemokine 
production, and development of heart failure [72]. Expression of IFNγ was highly upregulated 
in an Ang II-induced model of hypertension [31], and IFNγ-deficient mice had reduced heart 
infiltration by macrophages, which was associated with decreased fibrosis [73, 74]. 
Additionally, transgenic mice with constitutive expression of IFNγ spontaneously developed 
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myocarditis characterized by inflammation, fibrosis, ventricular wall thinning and dilation as 
well as reduced systolic function [72, 75]. Clinical data are in line with these animal models 
and suggest a positive association between IFNγ and disease development [76, 77].  
In contrast, other reports revealed the protective effect of IFNγ. Garcia et al. showed that 
IFNγ-deficient mice have greater heart hypertrophy as compared to wild-type (WT) animals 
upon aldosterone infusion [78]. Furthermore, administration of IFNγ attenuated myocardial 
hypertrophy in the rat aortic banding model of pressure overload. Marko et al. demonstrated 
that in spite of reduced interstitial fibrosis, IFNγ-/- mice have more pronounced podocyte 
injury in the Ang II-induced model of hypertensive organ damage [74]. Not only IFNγ but also 
STAT1 was found to be involved in pathophysiology of CVDs. Agrawal et al. identified STAT1 as 
an important regulator of foam cell formation and atherosclerotic lesion development [79]. 
STAT1 was identified to play a role in macrophage apoptosis, a critical process for the 
formation of necrotic core in atherosclerotic plaques [80]. Mice transplanted with STAT1 
deficient bone marrow revealed reduced macrophage apoptosis and plaque necrosis [80].  
 
Taken together, these data suggest that IFNγ together with downstream activated STAT1 play 
a role in the cardiovascular system. However, whether this role is detrimental or protective  
in the development of CVDs is still not fully understood and should thus be elucidated.  
 
IFN and IRFs 
 
Response to IFNγ can be divided into two phases. In the early phase, phosphorylated STAT1 
activate genes containing the GAS sequence in their promoters (e.g. Cxcl9). Among these 
genes are also interferon regulatory factors (IRFs) [81] (Fig. 1-5).  
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Fig. 1-5. Phylogenetic relation and structure of the interferon regulatory factors (IRFs). The N-terminal 
region of each IRF contains DNA binding domain with five preserved tryptophan residues which form helix-
turn-helix structure and recognizes specific DNA sequence e.g. ISRE. Except IRF6, all IRFs contain IRF-
association domain (IAD) that allows them to interact with other proteins. Some IRFs contain repression 
domain and nuclear localization signal domain. Additionally IRF1, IRF2, IRF3 and IRF7 are prone to 
posttranslational modification e.g. phosphorylation. 
 
These IRFs, by recognizing the modulatory elements, e.g. the interferon stimulated response 
element (ISRE), trigger the second wave of reaction to the IFNγ. The family of IRFs comprises  
9 members that share structural similarities [82]. A crucial function of the IRFs in modulation 
of the transcriptional response is not only based on their ability to directly recognize 
conserved sequences of target genes, but also on their interaction with other members of the 
IRF family or other co-factors [83]. IRF3, IRF7, IRF9 play an important role in response to type I 
interferons. Activated IRF3 and IRF7 induce expression of type I interferons and IRF9 
participates in formation of the STAT1-STAT2-IRF9 complex and induces transcription of 
interferon-stimulated genes [84]. In turn, IRF1 and IRF8 play a particularly important role in 
IFNγ response [51]. Interestingly, recent studies indicate that IRF1 is not only a downstream 
gene of STAT1 but can also interact with it, thus forming a complex that affects expression  
of interferon-stimulated genes [85]. Moreover, Wessely et al. revealed an important role of 
IRF1 in neointimal growth after vessel injury and suggested IRF1 as a target for interventions 
to prevent hyperplasia [86]. Unlike STAT1 and IRF1, which are ubiquitously expressed,  
IRF8 expression is thought to be restricted to lymphoid-cell lineages such as B, T and dendritic 
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cells and macrophages. IRF8 can not only recognize the ISRE element but also, together with 
other transcription factors including PU.1, it can bind to elements recognized by STAT1 
(the GAS element) [87]. Thus, IRF8 may create a feedback loop for some STAT1-activated 
genes and partially account for the “immune cell-specific” STAT1-dependent functions of IFNγ 
[87]. Interestingly, recently we obtained evidence that IRF8 is highly expressed in ECs and 
VSMCs after IFNγ treatment (Chapter 3), thus suggesting that it can also regulate “vasculo-
specific” STAT1-dependent functions of IFNγ. Moreover, recent data indicate the function of 
IRF8 in pathological cardiac hypertrophy or atherosclerosis [88, 89]. Although the mechanism 
is not clear, it is tempting to speculate that IRF8 specifically regulates STAT1-dependent IFNγ-




Toll-like receptors (TLRs) belong to the group of PRRs that play a pivotal role in the first line  
of defense against pathogens. Until now, 10 TLRs have been identified in humans (Fig. 1-6).  
 
Fig. 1-6. Pathogen recognition receptros (PRRs) and their ligands. Most of the PRRs are located on the cell 
surface but some receptors are also present in cytosol and endosome. PRRs are activated by multiple PAMPs 
and thus create first line of defense against infection. All TLRs and their adapters contain highly conservative 
Toll/IL-1 domain. The adapter protein myeloid differentiation primary response protein-88 (MyD88) seems to 
be involved in signaling by all TLRs, but not TLR3. TLR4, as the only member of the family, utilizes all four 
described TIR-containing adapters. 
 
They are expressed on a variety of cell types and play a distinct function in immune 
recognition [90]. In addition to multiple exogenous PAMPs, TLRs are activated by various 
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endogenous DAMPs; for example, bacterial lipoproteins and lipoteichoic acid are recognized 
by TLR2, double-stranded RNA by TLR3 and LPS by TLR4 and TLR2. Likewise, TLR4 recognizes 
DAMPs related to stress or injury of the host, which include heat shock proteins (HSP), 
fibrinogen, extra domain A of fibronectin and soluble hyaluronan [91]. All TLRs and their 
adapters contain highly conservative Toll/IL-1 domain [92, 93]. The adapter protein myeloid 
differentiation primary response protein-88 (MyD88) seems to be involved in signaling by all 
TLRs, but not TLR3 [94]. TLR4, as the only member of the family, utilizes all four of the 
described TIR-containing adapters. TLR4 together with MD2, CD14 and LBP form a complex 
that recognizes LPS [95]. Response to LPS can be divided into two stages: binding of LPS to the 
receptor complex located on the cell surface initiates the early phase of activation of  
the nuclear factor-kappa B (NFκB) through TIR domain-containing adaptors TIRAP (Mal) and 
MyD88. Subsequently, the TLR4-MD2-LPS complex is internalized to the endosome and used 
by TRIF and TRAM to activate NFκB. Interestingly, both phases of the response are necessary 
to activate NFκB [95]. Together this leads to the induction of various target genes that include 
type I IFNs (through IRF3), chemokines and cell surface molecules.  
 
There is a large number of research studies indicating the importance of the TLR4 pathway in 
the cardiovascular field [96]. Michelsen et al. showed that mice lacking either TLR4 or MyD88 
had reduced atherosclerosis correlated with reduced levels of inflammatory cytokines [97]. 
TLR4 was found to be overexpressed in the VSMCs of atherosclerotic arteries, even in regions 
with few inflammatory cells [98]. Other studies pointed to the role of TLR4 in intimal foam cell 
accumulation [99]. Expression of TLR4 was upregulated in patients with unstable angina and 
acute myocardial infarction [100]. Recent studies support the role of TLR4 in hypertension.  
An elevated level of TLR4 was found in spontaneously hypertensive (SHR) rats as well as in  
the L-NAME-induced model of hypertension and blocking of TLR4 reduced blood pressure, 
inflammation and maximal mesenteric artery contractile response to noradrenaline [29, 101, 
102]. Furthermore, experiments performed in our laboratory provided evidence for the direct 
role of TLR4 on vascular contractility and blood pressure [103]. The blood pressure of  
TLR4-deficient mice was not increased upon treatment with L-NAME. This effect was 
associated by decreased production of reactive oxygen species (ROS) which are known to 
affect the contraction apparatus of the vessel [104, 105].  
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STAT1 and IRFs involved in TLR signaling 
 
As is shown on Figure 1-7, stimulation of TLR4 leads to the phosphorylation of IRF3 and 
consequently to expression of IFNβ (type I IFN).  
 
IFNβ in the autocrine/paracrine loop bind to its receptor and activate the pathway. Similarly 
to IFNγ, conformational changes of the receptor facilitate recruitment of the JAK1 and TYK2 
kinases which enable formation of predominantly STAT1-STAT2 heterodimers and STAT1 
homodimers. Complexes containing STAT1 are transferred to the nucleus. Then the STAT1-
STAT2 heterodimers recruit IRF9 (called ISGF3) that bind to promoter regions of genes 
containing ISRE, whereas STAT1-STAT1 homodimers bind to GAS elements [43, 106].  
It is worth noting that both type I and type II IFN (IFNγ) pathways share common features. 
These two pathways utilize similar transcription factors, e.g. STAT1, IRF1 or IRF8, and 
transcription factor complexes, and as such regulate partially overlapping genes [107].  
Many of the genes (including Cxcl9, Ccl2, Ccl5, Isg15 and Nos2) activated by the TLR pathway 
are regulated secondary to LPS-induced type I IFN in a STAT1-dependent manner [108]. 
Activation of IFN is essential to develop a full transcriptional response to TLR4 stimulation;  
for example, macrophages from Tyk2-deficient mice fail to produce nitric oxide (NO) following 
Fig. 1-7. Components of the JAK/STAT 
pathway are involved in a TLR signaling. 
Stimulation of TLR4 allows TIR domain to 
interact with accessory molecules which 
leads to the activation of Myd88 and 
TRAM. Myd88 activates NFκB, which 
induces expression of inflammatory 
cytokines. TRAM activates IRFs e.g. IRF3, 
IRF8. IRF3 is phosphorylated, 
homodimerizes and induces IFNβ 
production, which in an auto- and 
paracrine manner can stimulate cells to 
induce IRF1 and STAT1 in the JAK/STAT 
dependent manner. Other IRFs e.g. IRF8 
during TLR activation interacts with other 
transcription factors leading to 
inflammatory gene expression. 
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LPS stimulation [109]. As such, STAT1 has been identified as an important mediator in  
the biological response to TLRs, including TLR4. These studies were further supported by the 
observation that Socs1 (negative regulator of STAT1 action)-deficient macrophages have 
increased sensitivity to TLR4 ligands such as LPS and palmitic acid [110]. In addition to IRF3, 
IRF1, IRF5, IRF7 and IRF8 were shown to contribute to TLR-mediated signaling [82].  
Direct interaction of IRF1, IRF5 and IRF7 with MyD88 allows for their activation and 
subsequent translocation to the nucleus, where they can induce gene expression [111-113]. 
IRF8-deficient mice fail to induce TLR9-mediated expression of IL6 and TNFα [114]. IRF8 also 
facilitates TLR2- and TLR4-mediated induction of interleukins, NO synthase and TNFα [115]. 
Moreover, macrophages from IRF8−/− mice produce diminished levels of TNFα, IL1β and 
IL12p70 in response to LPS [116].  
 
Crosstalk between IFNγ and TLR 
 
In physiological conditions the action of immune cells is regulated by the activity of many 
stimuli. Exposure to one cytokine followed by stimulation with the same or different stimuli 
may cause either synergistic or antagonistic effects [117]. A similar situation occurs with 
respect to IFNγ, whose pleiotropic action cannot be explained only by the direct function of 
STAT1 on target genes [118]. Crosstalk between IFNγ and TLRs has been associated with host 
defense against pathogens and injury, but can also contribute to pathophysiology of chronic 
inflammatory diseases such as rheumatoid arthritis [119]. Indeed, stimulation of DCs and 
macrophages with IFNγ is required to enhance TLR signaling and thus efficient induction  
of inflammatory mediators [120, 121]. Moreover, it has been shown that IFNγ breaks 
tolerance toward endotoxins (the ligands of TLRs) and increases expression  
of proinflammatory genes [122]. There are several proposed mechanisms describing 
functional cooperation between IFNγ and TLRs. First, IFNγ not only upregulates expression of 
genes related to TLR signaling such as receptors or genes that participate in signal 
transduction [120, 123, 124], but also inhibits the negative feedback loop by abrogation of 
IL10 expression as well as the transcriptional repressors Hes1 and Hey1 [118]. IL10 is an 
important anti-inflammatory mediator induced by TLR4 to inhibit the inflammatory actions  
of genes such as TNFα [125]. IFNγ increases the activity of serine/tyrosine kinase GSK3β which 
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in turn inhibits the action of AP-1 and CREB. These two transcription factors are mandatory in 
order to induce expression of the Il10 gene, thus inhibition of their action ameliorates the 
expression of IL10 [126]. Furthermore, IFNγ suppress the action of Hes1 and Hey1 repressors 
and thus augments expression of genes related to inflammation, e.g. IL6 and IL12 [127].  
 
IFNγ and STAT1 not only inhibit the negative feedback loop but also enhance positive 
signaling. Since the discovery that STAT1 can be phosphorylated upon LPS stimulation,  
the role of STAT1 as an important mediator of the crosstalk between IFNγ and TLR4 has been 
appreciated. Increased phosphorylation of STAT1 and cooperation of STAT1 with other 
transcription factors may play a role in this amplification mechanism (Fig. 1-8).  
 
Indeed, it has been shown that the activity of STAT1 is enhanced by TLR-dependent induction 
and the subsequent autocrine activities of IFNγ [108, 128, 129]. In contrast, stimulation of 
macrophages with another TLR ligand, CpG DNA, did not affect phosphorylation of STAT1 and 
as a consequence did not influence synergistic amplification of the inflammatory genes. 
Because CpG stimulation does not affect expression of type I IFN, this experiment confirms 
the importance of the type I IFN autocrine loop in the crosstalk between IFNγ and TLR4 [130]. 
Other studies indicate that STAT1 cooperation with other transcription factors such as NFκB 
Fig. 1-8. Functional crosstalk between 
JAK/STAT and TLR pathway. IFNγ may 
inhibits the negative feedback loop 
(details in text). JAK/STAT and TLR4 
pathway use STAT1 to elicit cell 
response. Increased phosphorylation 
of STAT1 upon treatment with IFNγ 
and LPS together with cooperation of 
STAT1 with other transcription factors 
like NFκB or IRFs play an important 
role in the amplification mechanism in 
immune cells. 
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at the level of target gene promoters is mandatory for the synergistic amplification of 
inflammatory genes [120].  
 
These phenomena were observed for example for an expression of chemokines such as Cxcl9, 
Cxcl10 adhesion molecule Icam1 or Nos2 in response to IFNγ and LPS or other inflammatory 
mediators [131-137]. In addition, STAT1 targets IRF1 and IRF8 have also been shown to 
contribute to signal integration between IFNγ and LPS. Sequences recognized by both STAT1 
and NFκB were found in the promoter regions of IRF1, thus indicating that not only IFNγ but 
also TLR agonists can regulate expression of IRF1 [138-141]. Similarly, cooperation between 
IRF1 and NFκB was found to be involved in the transcriptional regulation of Cxcl10 and Nos2 
(iNOS) [142, 143]. Moreover, other reports have suggested the role of IRF8 in IFNγ- and  
LPS-mediated synergistic induction of pro-inflammatory genes such as Il1, Il6, Il12 and Tnfα  
as well as the chemokine Ccl5 (RANTES) [115, 144]. These findings suggest that in immune 
cells, STAT1 and IRFs together with NFκB coordinate antimicrobial and inflammatory 
synergism between IFNγ and TLRs. 
 
Recently, a new mechanism of signal integration between IFNγ and TLR4 has been proposed 
[85]. This mechanism is based on epigenetic changes triggered by IFNγ which augments 
expression of TLR4 downstream genes. Qiao et al. suggested that IFNγ-activated STAT1 affects 
histone acetylation and thus causes increased and prolonged recruitment of additional 
transcription factors and pol II after TLR4 stimulation. Consequently this mechanism increases 
transcription of proinflammatory genes. As such, STAT1 may not only be considered as  
a transcription factor but also as an element that initiates chromatin remodeling.  
 
Most studies performed so far have indicated the importance of signal integration between 
JAK/STAT and TLR4 pathways in immune cells. However, our knowledge about this functional 
cooperation in non-immune cells is limited.   
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Goals /Scope of the thesis 
 
We hypothesized that STAT1- and IRF-mediated gene expression accelerates an inflammatory 
response, which negatively affects the cardiovascular system.  
In Chapter 2 we introduce the concept of signal integration in non-immune cells represented 
by ECs, VSMCs and proximal tubular cells. Data presented in this chapter provide evidence for 
crosstalk between IFNγ and LPS. Increased activity of STAT1 and IRF1 resulted in amplified 
expression of proinflammatory cytokines Cxcl10, Cxcl9, Ccl5 and an inducible nitric oxide 
producer – Nos2 (iNOS). Thus we consider STAT1 as a novel target for therapeutic intervention 
also in non-immune cells.  
In Chapter 3 we elucidate the role of STAT1 and IRF8 in mediating the interplay between  
a damaged organ and host immunity. In this chapter we present the results of a genome-wide 
analysis in VSMCs which identified a set of STAT1-dependent genes that were synergistically 
affected by interactions between IFNγ and TLR4. Among the highly amplified genes we 
distinguished not only chemokines, adhesion molecules, antiviral and antibacterial genes,  
but also the gene encoding Irf8, the transcription factor that was not known to be expressed 
in the vasculature. We identify Ccl5 and Nos2 as the potential targets of Irf8. Finally,  
the functional assays together with the immunohistochemical stainings of phosphorylated 
STAT1- and STAT1-dependent genes presented in this chapter support the importance of 
STAT1 in the regulation of vascular inflammation.  
Data presented in Chapter 4 disclose the role of STAT1 as an important regulator of 
inflammation and vessel function in the model of Ang II-induced hypertensive end organ 
damage. Compared with the control, STAT1-deficient animals infused with Ang II had 
ameliorated immune cell infiltration of the heart and kidney, reduced fibrosis and, foremost, 
improved vessel function. We identified several STAT1-dependent genes that may participate 
in the progression of vascular damage and thus contribute to progression of the disease. 
Among them, Cxcl10, Ccl2 and Cxcl10 chemokines and proteins involved in regulating 
oxidative stress (Nox4, p47phox, p22phox) revealed to be regulated by STAT1. Interestingly, 
despite diminished CD45+ cell infiltration and expression of fibrotic markers, STAT1-/- animals 
as compared to wild type (WT) animals had a significantly higher concentration of urinary 
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albumin, thus indicating increased glomerular damage. We hypothesize disturbance of 
autophagy to be a cause of albuminuria in STAT-/- and suggest a novel role of STAT1  
in response to stress in the kidney.  
Chapter 5 summarizes findings presented in the thesis and discuss potential applications as 
well as future research directions.  
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Chapter 2  




Cell signaling is a complex system that facilitates perception and reaction to stimuli. Proper 
processing of the signaling is mandatory for the functioning of cells, tissue homeostasis and, 
consequently, survival of the organism as a whole. Many diseases are related to improper 
response to intra- or extracellular ligands. Until very recently scientists studied linear signaling 
cascades; however, because cells have to integrate multiple signals in order to regulate 
manifold cellular processes, it became clear that there must be crosstalk between them. 
Inflammation is a sophisticated mechanism of response to an infectious agent and injury 
[145]. This mechanism is based on a complex cell signaling network that maintains 
homeostasis of the host. However, in certain conditions the system that prevents injury may 
contribute to its progression. Excessive inflammation is involved in the pathophysiology of 
many diseases, including atherosclerosis, aortic aneurysm formation or acute kidney injury. 
One of the essential contributors of inflammation is IFNγ, which is produced mostly by  
T and NK cells [38-42]. IFNγ signaling plays an important role in innate and adaptive immunity 
by activating immune cells such as macrophages or T cells. Recent evidence have indicated the 
significance of IFNγ signaling in non-immune cells; for example, in the absence of immune 
cells, IFNγ can cause proliferation of SMCs in the media layer of the vessel wall [68].  
IFNγ-dependent chemokines, such as Cxcl10 (IFN-induced protein of 10 kDa, or IP10) or Cxcl9  
(a monokine induced by IFNγ or MIG), are highly expressed upon stimulation in endothelial 
cells (ECs) and vascular smooth muscle cells (VSMCs), and are present in dysfunctional vessels 
[146-149]. Other studies revealed that IFNγ deficient mice demonstrated decreased 
tubulointerstitial damage upon treatment with Angiotensin [74]. The signal transducer and 
activator of transcription (STAT)-1 is a canonical mediator of IFNγ signaling. Activation of 
STAT1 by IFNγ leads to its phosphorylation and formation of the dimer that triggers expression 
of STAT1-dependent genes. Importantly, recent experiments performed in macrophages have 
shown that STAT1 is not only involved in the activation of the JAK/STAT pathway, but also 
contributes to signaling events mediated by Toll-like receptor 4 (TLR4) [108, 150]. 
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TLR4 belongs to the receptor family that recognizes pathogen-associated molecular patterns 
such as lipopolysaccharide (LPS) and activates expression of proinflammatory genes.  
In the second stage of the response to TLR4 stimulation, TIR-domain-containing adapter-
inducing interferon-β (TRIF) triggers phosphorylation of transcription factor IRF3 and 
consequently expression of IFNβ which, in turn, facilitates activation of STAT1 [151]. 
Moreover, IFNγ can sensitize immune cells to the action of LPS, which greatly amplifies the 
inflammatory response [152]. Thus STAT1 may be considered as an important point of 
crosstalk between LPS and INFγ signaling in macrophages [120].  
In this chapter we provide evidence to support the idea that in addition to the immune 
system, signal integration between these two pathways is present in other tissue types.  
IFNγ-mediated activation of STAT1 serves as a platform for increased LPS signaling, resulting in 
augmented STAT1 phosphorylation and expression of genes related to chemotaxis and 
oxidative stress. As evidence for this concept we use inhibitors of the JAK/STAT pathway that 
are known to affect directly (stattic) or indirectly (Ag490 – JAK2 inhibitor) the action of STAT1. 
 




Human Microvascular Endothelial Cells (HMECs) obtained from Centers for disease control 
and prevention (Atlanta, GA, USA) were cultivated in MCDB-131 (Life Technologies) medium 
containing 10% FBS (PAA), 100U/ml penicillin, 100μg/ml streptomycin, 0.01µg/ml EGF, 
0.05µM hydrocortisone (Sigma), 2mM L-glutamine (PAA). 
 
Isolation of primary VSMC 
WT mice (strain background C57BL/6) were obtained from Charles River Laboratories 
(Sulzfeld, Germany). Primary Vascular Smooth Muscle cells (VSMCs) were isolated by 
enzymatic digestion [153] in a solution containing collagenase type II 1mg/ml, soybean trypsin 
inhibitor 1mg/ml (Life Technologies), elastase 0.744u/ml (Sigma) in HBSS (Life Technologies). 
Isolated aortas from 2 mice were cleaned from perivascular fat and predigested for 10min. 
Subsequently adventitia was removed, aortas were cut lengthwise and intima was removed 
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by gentle scraping. So prepared aortas were enzymatically digested for 1h at 37˚C. After 
digestion aortas were passed through 100µm cell strainer (BD Falcon) and left undisturbed on 
3 wells of a 48 well plate for 1 week. Until passage number 3 cells were cultivated in DMEM 
(PAA) medium with 20% FBS. After 3rd passage SMC were cultivated in DMEM (PAA) medium 
containing 4.5mg/l Glucose, 2mM L-glu, supplemented with 100U/ml penicillin and 100μg/ml 
streptomycin and 10% FBS (PAA). Homogeneity of the culture was assessed by the expression 
of α-smooth muscle actin, calponin and smoothelin.  
 
Isolation of tubular cells 
Freshly isolated kidneys were minced and placed in a HBSS solution containing collagenase II, 
1mM HEPES and 100U/ml penicillin, 100µg/ml streptomycin (Life Technologies). After 1h 
incubation at 37˚C in water bath, solution were sieved over a 70µM cell strainer and 
centrifuged. Subsequently cells were washed and resuspended in the DMEM/F12 medium 
containing GlutaMAX (Life Technologies) with 5% FBS (Sigma), 25mM HEPES, 100U/ml 
penicillin, 100µg/ml streptomycin (Life Technologies), 25ng/ml epidermal growth factor 
(Sigma) and 5ml of hormone mixture containing Insulin (0.5mg/ml), PGE1 (0.125µg/ml), 
Triiodothyronine (3.38ng/ml), Hydrocortisone (1.8µg/ml), Transferrin (0.173µg/ml) and 
Sodium Selenite (0.5mg/ml) (Sigma). Cell were placed on a collagen covered plate and used 
for the experiments after second splitting. Homogeneity of the culture was assessed by the 
expression of sodium/potassium-transporting ATPase gamma chain (FXYD2). 
 
Isolation of splenocytes  
Freshly isolated spleens were placed in the RPMI 1640 (Life Technologies) medium containing 
25mM Hepes (Gibco), 1% FBS (Sigma), 2mM L-glutamine, 100U/ml penicillin, 100µg/ml 
streptomycin (PAA). Afterwards, spleens were minced with scalpel and passed through pre-
wetted 70µm and 40µm cell strainers (BD Biosciences). To lyse red blood cells, cell suspension 
was centrifuged and resuspended in RBC lysis buffer (eBiosciences). After 45sec of incubation 
medium was added and cells suspension was centrifuged. Next, cells were counted and 
treated with indicated concentration of either LPS or IFNγ or both. 
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In general, all cells were treated with 10ng/ml of IFNγ and/or 1µg/ml of LPS. Treatment of 
VSMCs and HMECs was performed in medium containing 2% (splenocytes in 1%) serum 
without the addition of growth factors (starving medium), after starvation of at least 12h 




Protein extracts from cells as well were prepared using RIPA buffer (Sigma) containing 
protease and phosphatase inhibitors (Roche). Cell lysates were collected and stored at -80°C. 
Protein concentrations were measured using BCA protein assay (Pierce). Protein extracts were 
heated with sample buffer (Life Technologies) containing dithiothreitol (90˚C, 10min) and 
loaded on NuPAGE Bis-Tris Gel (Life Technologies). After electrophoresis (200V, 40min to 1h 
30min, depending on protein size), proteins were transferred onto PVDV membranes 
(Millipore) using wet transfer system (Bio-rad, 30V, 90mA, 16h at 4˚C). Membranes were 
blocked either with 5% nonfat dry milk or with 5% BSA in TBS-Tween (TBST) and incubated 
with primary antibodies: phospho-STAT1 (Tyr 701) antibody (overnight, 1:1000, Cell Signaling, 
cat no. 3171 ), phospho-STAT1 (Ser 727) (overnight, 1:1000, Cell Signaling, 8826), STAT1 (1h at 
room temperature, 1:200 Santa Cruz, SC346) or GAPDH (overnight, 1:15000, Cell Signaling, 
5174). After washing in TBST, membranes were incubated with secondary goat anti-rabbit 
antibody (30min 1:10000 for STAT1 and 1:15000 for all the others, Santa Cruz Biotechnology 
SC2004). Antibody-antigen complexes were visualized using Luminata Forte or Luminata 
Classico (only for GAPDH) Western HRP substrate (Millipore) in INTAS imaging system (Intas, 
Germany). 
 
Measurement of nitric oxide (NO) 
VSMCs were treated as depicted in cell experiment section. After treatment medium was 
refreshed and cells were cultivated for further 24h. Subsequently, medium was collected and 
100ul was used to measure amount of NO by Griess diazotization reaction [154]. Medium was 
incubated with freshly prepared solution containing 1% sulfanilamide 5% HCl, 0.1% aqueous 
solution of 2-(1-Naphthylamino)ethylamine dihydrochloride (Sigma). After 10min incubation 
OD at 560mm was measured and compared to the standard curve. 
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RNA isolation and PCR and real-time PCR 
Total RNA was isolated using RNAeasy Mini Kit (Qiagen, Hilden, Germany) together with 
DNAse digestion step according to the manufacture’s protocol. Complementary DNA was 
synthesized using iScript cDNA Synthesis Kit (Bio-Rad, Hercules, USA), according to 
manufacturer’s protocol. Quantitative reverse transcriptase PCR (qRT-PCR) was performed 
using SSoFast Evagreen (MyiQ ICycler, Bio-Rad). Forward and reverse primers are depicted in 
Table 2-1. The 2-ddCt method was applied for quantification [155]. Fold change in the target 
gene were normalized to GAPDH and relative to the expression at untreated sample.  
 
Table 2-1. List of primers used in chapter 2. 
Gene Name Forward  Reverse 
Gapdh TCGGTGTGAACGGATTTGGC TTTGGCTCCACCCTTCAAGTG 
α-actin CAACTGGTATTGTGCTGGACT GAAAGATGGCTGGAAGAGAGT 
calponin ACGGCTTGTCTGCTGAAGTA AAGATGTCGTGGGGTTTCAC 
smoothelin AGAACTGGCTACACTCTCAAC GGGTCCAATGTGTGTGCTG 
Ccl5 (Rantes) CGCACCTGCCTCACCATAT CACTTCTTCTCTGGGTTGGC 
Cxcl10 TCATCCCTGCGAGCCTATCC GGAGCCCTTTTAGACCTTTTT 
Cxcl9 CTGCCATGAAGTCCGCTGTTCT TCCCCCTCTTTTGCTTTTTCTT 
iNOS (nos2) TGGGGCAGTGGAGAGATTTT TCTGGTCAAACTCTTGGGGT 
FXYD2 ATGGCTGGGGAAATATCAGAT ACCTGCCTATGTTTCTTACCG 
IRF1 AAAAGAGCCAGATCCCAAGAC AACATCTCCACACAGCTTCC 
STAT1 AACATACGGAAAAGCAAGCG GCTGTTCCTGTTTTTGGTCG 
TNFα Qiagen cat no. QT00104006 
Gapdh_human CAACTGCTTAGCACCCCTGG CAGGTCAGGTCCACCACTGA 
Ccl5 human CCCTCGCTGTCATCCTCATT GTGACAAAGACGACTGCTGG 
Cxcl10 human CGTGTTGAGATCATTGCTACAA GACCTTTCCTTGCTAACTGCT 
Cxcl9 human GTGGTGTTCTTTTCCTCTTGGG CTCACTACTGGGGTTCCTTGC 
 
Data analysis 
Statistical analysis: Results are expressed as mean ± SEM for at least 3 experiments. Data were 
compared by a One Way ANOVA and the Tukey post-hoc test or T-test, when appropriate.  
A probability value p<0.05 was considered statistically significant. All statistical tests were 
performed with GraphPad Prism ® 5.0.  




IFNγ sensitizes splenocytes for LPS-induced STAT1-phosphorylation and target gene 
expression. 
To verify in our laboratory presence of the signal integration between IFNγ and LPS in immune 
cells, we isolated splenocytes from C57BL/6 mice. Spleen is the largest secondary immune 







Fig. 2-1. Signal integration between IFNγ and LPS in splenocytes. Isolated splenocytes from  
3 animals were treated with 10ng/ml of IFNγ for 8h or 1 μg/ml of LPS for 4h, or both. A, Protein 
extracts were analyzed by western blotting for tyrosine phosphorylated STAT1 (pSTAT1), total 
STAT1 and GAPDH. Beside classical presentation, palette of inverted false colors for pSTAT1 was 
applied where white indicates low and blue high intensity of the band. B, Splenocytes were 
treated as in A. RNA was isolated and subjected to qRT-PCR for Cxcl10, Cxcl9, Ccl5 and iNOS. 
p<0.05 was considered significant.  
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Preliminary experiments (verifying different time points and ligand concentrations) performed 
in our laboratory revealed that the highest level of sensitization for the action of LPS occurs when 
the cells are treated with 10ng/ml of IFNγ for 4h followed by 1µg/ml of LPS for another 4h.  
Pretreatment of splenocytes with such a conditions (Fig. 2-1 A) resulted in a significant 
increase in STAT1 phosphorylation as compared to both factors alone. Increased STAT1 
expression was also observed and was strictly dependent on IFNγ (Fig. 2-1 A). Next, we 
examined expression of proinfnlammatory genes, chemokines: Cxcl10, Cxcl9, Ccl5 and 
inducible nitric oxide producer – Nos2 (iNOS) (Fig. 2-1 B). We identified chemokine Cxcl10 and 
Nos2 as genes that are synergistically amplified upon combined treatment. Both were 
expressed moderately upon treatment with IFNγ or LPS alone and highly amplified in the 
presence of IFNγ and LPS (Fig. 2-1 B, left panel). These results correlated with increased STAT1 
phosphorylation (Fig. 2-1 A). On the contrary we could not detect significantly increased 
mRNA levels of both Cxcl9 and Ccl5 treated with IFNγ and LPS compared to both factors alone 
(Fig. 2-1 B, right panel). Interestingly, expression pattern of this two genes were different. 
Cxcl9 expression was IFNγ dependent and LPS independent whereas Ccl5 was expressed only 
upon treatment with LPS.  
 
IFNγ sensitizes SMCs and ECs for LPS-induced STAT1-phosphorylation and target gene 
expression. 
Next, we studied the possibility of STAT1-dependent cross-talk in cells from the vasculature. 
We isolated primary VSMCs from C57BL/6 aortas according to the method described  
in section material and methods. Representative picture of isolated VSMCs is present in  
Fig. 2-2 A.  
Fig. 2-2. Isolation of aortic VSMCs and 
assessment of their homogoenity. Cells 
were isolated by enzymatic digestion. 
Representative picture of cultivated VSMCs 
is given in A. B, To evaluate homogeneity of 
the culture, RNA was isolated and subjected 
to PCR for α-acitn, smoothelin and calponin. 
All cells expressed markers characteristic 
for VSMCs. 
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Assessment of the homogeneity was performed using markers specific to VSMCs (Fig. 2-1 B). 
Indeed, VSMCs expressed α-actin, smoothelin and calponin that are characteristic for VSMCs 
[157]. Pretreatment of VSMCs with IFNγ for 4h followed by LPS for another 4h resulted in  
a significant increase in STAT1 phosphorylation as compared to both factors alone (Fig. 2-3 B). 
Increased levels of phosphorylated STAT1 were correlated with synergistic amplification of 









Fig. 2-3. Signal integration between IFNγ and LPS in VSMCs. A, Isolated primary VSMCs from murine 
aortas were treated with 10ng/ml of IFNγ for 8h or 1 μg/ml of LPS for 4h, or both. RNA was isolated 
and subjected to qRT-PCR for Cxcl10, Cxcl9, Ccl5. B, VSMCs were treated as in A. Expression of Nos2 
upon stimulation (left panel) and the product of Nos2- nitrite in the conditioned medium (right 
panel) was investigated. p<0.05 was considered significant. C, VSMCs were treated as in A. Protein 
extracts were analyzed by western blotting for pTyrSTAT1, total STAT1 and GAPDH. Beside classicall 
visualsation, palette of inverted false colors for pTyrSTAT1 was applied where white indicates low and 
blue high intensity. Represenative picture is present.  
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Interestingly, 3 different chemokines revealed 3 different patterns of expression upon 
treatment suggesting different mechanism of activation. Cxcl10 (Fig. 2-3 A,) was highly 
expressed upon treatment with IFNγ and LPS alone and combined treatment synergistically 
amplified this response. Expression of Cxcl9 (Fig. 2-3 A, middle panel) upon treatment with LPS 
was very low compared to IFNγ stimulation and highly amplified in the presence of both.  
In contrast expression of Ccl5 was very low upon treatment with IFNγ, highly expressed with LPS 
and synergistically amplified in the presence of both stimuli (Fig. 2-3 A). Likewise expression of 
Nos2 (iNOS) was high upon treatment with LPS and highly amplified upon combined treatment 
(Fig. 2-3 C). The RNA levels reflected nitrite accumulation for Nos2 (Fig. 2-3 C, lower panel).  
Because we were not able to isolate a homogeneous population of endothelial cells (data not 
shown), we instead used the human microvascular endothelial cell line (HMEC). This cell line 
retains morphologic, phenotypic, and functional characteristics of normal microvascular ECs 
[158]. Similarly to VSMCs, synergistic expression of chemokines Cxcl10, Cxcl9 and Ccl5 was 
identified in HMECs treated with IFNγ and LPS (Fig. 2-4 A), which coincided with STAT1 





Fig. 2-4. Signal integration between IFNγ and LPS in HMECs. A, Cultivated HMECs were treated with 10ng/ml of 
IFNγ for 8h or 1 μg/ml of LPS for 4h, or both. RNA was isolated and subjected to qRT-PCR for Cxcl10, Cxcl9, Ccl5. 
p<0.05 was considered significant. B, HMECs were treated as in A. Protein extracts were analyzed by western 
blotting for pTyrSTAT1, total STAT1 and GAPDH. Beside classicall visualsation, palette of inverted false colors for 
pTyrSTAT1 was applied where white indicates low and blue high intensity. Represenative picture is present.  
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Likewise, expression of the chemokines had the same profile as in VSMCs. Moreover,  
we observed that pretreatment of HMECs with IFNγ for 4h followed by LPS for another 4h 
resulted in a significant increase in STAT1 phosphorylation as compared to both factors alone 
(Fig. 2-4 B). Increased STAT1 protein levels, strictly dependent on IFNγ, could provide a 
possible explanation for the increased STAT1 phosphorylation under conditions when both 
IFNγ and LPS are present. 
 
Signal integration is present in proximal Tubular cells. 
Similarly to cells from the vasculature also tubular epithelial cells are the target of 
inflammatory response [159]. Thus to support hypothesis that signal integration is present  
in non-immune cells, we isolated proximal tubular cells from C57BL/6 mice. Representative 
picture of tubular cells is present in Fig. 2-5 B Homogeneity of the isolated cells was assessed 
by expression of FXYD2.  
Isolated cells expressed high levels of FXYD2, marker for tubular cells and low levels  
of calponin which is preferentially expressed in smooth muscle cells (Fig. 2-5) [157].  
 
 
Next, we analyzed expression and activity of STAT1 protein. Treatment with either IFNγ alone 
or together with LPS revealed upregulation of STAT1 expression (Fig. 2-6 A). In contrast to cell 
from the vasculature, we could not detect neither increased STAT1 expression upon combined 
treatment nor phosphorylation upon treatment with LPS alone. Interestingly, also 
Fig. 2-5. Isolation of proximal tubular cells 
and assessment of their homogoenity.  
A, To evaluate homogeneity of the culture, 
RNA was isolated and subjected to qRT-PCR 
for FXYD2 and calponin. All cells expressed 
marker characteristic for proximal tubular 
cells and were negative for calponin.  
B, Representative picture of cultivated 
proximal tubular cells. 
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phosphorylated serine was not different between IFNγ and IFNγ + LPS treated samples  
(Fig. 2-6 B). Subsequently, we examined expression of chemokines Cxcl10, Cxcl9, Ccl5 and 
Nos2 (Fig. 2-6 C). All investigated genes were moderately expressed upon treatment with IFNγ 
or LPS and synergistically amplified upon combined treatment. ELISA performed on the 
medium remained after treatment of proximal tubular cells with IFNγ and LPS, confirmed 




















Fig. 2-6. Signal integration between IFNγ and 
LPS in proximal tubular cells. A and B, Isolated 
primary proximal tubular cells were treated with 
10ng/ml of IFNγ for 8h or 1 μg/ml of LPS for 4h, 
or both. Protein extracts were analyzed by 
western blotting for pTyrSTAT1 (A), pSerSTAT1 (B) 
total STAT1 and GAPDH. Beside classicall 
visualsation, palette of inverted false colors for 
pSTAT1 was applied where white indicates low 
and blue high intensity. Represenative pictures are 
present. C, Tubular cells were treated as in A. RNA was isolated and subjected to qRT-PCR for 
Cxcl10, Cxcl9, Ccl5 and iNOS. D, Cells were treated as in A. On the medium remained after 
treatment ELISA for Cxcl19 was performed. p<0.05 was considered significant. N/a - not detected. 
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Promoter analysis of the potential STAT1-targets 
Next, to provide in silico evidence for the importance of STAT1 and to locate other 
transcription factors that potentially may be involved in the synergistic amplification of the 
gene expression, we searched their promoter regions for overrepresented motifs recognized 
by transcription factors (Fig. 2-7). Promoter analysis of the synergistically upregulated genes 
predicted the presence of STAT-NFκB and IRF-NFκB motifs, strongly suggesting the 
cooperative involvement of NFκB, STAT1 and/or IRFs in the transcriptional regulation of Cxcl9, 




Fig. 2-7. Promoter analysis of the Cxcl9, Cxcl10, Ccl5, Nos2. The promoter regions from -1000 to +100bp from 
transcription start site were searched for binding sites. Promoters for amplified STAT1 dependent genes were 
screened using GENOMATIX software (http://www.genomatix.de/ [160]) for binding sites. Predefined 
matrices were used (V$IRF1.01 V$ISGF3G.01 V$ISRE.01 V$ISRE.02V$CREL.01 V$NFKAPPAB.01 
V$NFKAPPAB.02 V$NFKAPPAB65.01 V$STAT.01 V$STAT1.01 V$STAT1.02). Only sites with core similarity 
above 0.85 were selected. Start indicates position of ATG codon. 
 
To further elucidate the role of STAT1 and IRF1 in tubular cells, we confirmed their expression 
by performing qPCR (Fig. 2-8). Abundance of STAT1 mRNA was in line with western results for 
tubular cells (Fig. 2-6 A, B). Treatment with IFNγ resulted in high amplification of STAT1 and 
IRF1 which was not significantly different after incubation with LPS. Subsequently, we verified 
NFκB activity in tubular cells. For that reason we analyzed expression of TNFα. Abundance of 
this cytokine depends directly on the activity of NFκB but not STAT1. Indeed, treatment with 
LPS resulted in increased expression of TNFα. Prestimulation with IFNγ slightly but not 
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significantly increased levels of TNFα suggesting that NFκB activity is not the primary factor 
that contributes to the synergistic amplification.  
 
 
Ag-490 and Stattic attenuates STAT1-dependent crosstalk between IFNγ and LPS.  
To obtain further evidence for a role of STAT1 and JAK/STAT pathway in cross-talk between 
IFNγ and LPS, we treated VSMCs and proximal tubular cells with IFNγ and LPS in the absence 
or presence of inhibitors that are known to affect either JAK2 (Ag490) or STAT1 (stattic)  
(Fig. 2-9). Indeed, Ag490 and stattic diminished expression of Cxcl10, Cxcl9, Ccl5, Nos2 in 
VSMCs and in proximal tubular cells (Fig. 2-9 A and B) compared to controls treated with IFNγ 
and LPS. Attenuated response to IFNγ and LPS in proximal tubular cells was confirmed by 
ELISA for Cxcl9 (Fig. 2-9 C). 
 
Fig. 2-8. Expression of STAT1, IRF1 and marker 
of NFκB activity, TNFα in tubular cells. Primary 
proximal tubular cells were treated with 
10ng/ml of IFNγ for 8h or 1 μg/ml of LPS for 4h, 
or both. RNA was isolated and subjected to 
qRT-PCR for STAT1, IRF1 and TNFα. p<0.05 was 
considered significant. N/S - not significant. 










The pleiotropic functions of IFNγ and LPS cannot be explained only by separate action of 
individual transcription factors such as STAT1 or NFκB. Indeed, another mechanism (called 
priming) by which IFNγ and TLR4 ligands achieve strong responsiveness was observed in 
immune cells. It was shown that prestimulation of macrophages with IFNγ and subsequent 
treatment with TLR4 agonists greatly amplified expression of downstream-dependent genes 
[152]. This crosstalk between IFNγ and TLR4 has a fundamental role in host response against 
pathogens, but it can also participate in the pathophysiology of many diseases. To date there 
Fig. 2-9. Crosstalk between IFNγ and LPS in VSMCs and proximal tubular cells is inhibited in the 
presence of Ag490 or stattic. Cells were treated with 10ng/ml of IFNγ for 8h and 1 μg/ml of LPS for 4 
hrs. A, VSMCs were pre-treated with Ag490 or Stattic for 12h and then treated as above. RNA was 
isolated and subjected to qRT-PCR for Cxcl10, Cxcl9, Ccl5 and iNOS. B, Proximal tubular cells. B. Proximal 
tubular cells were pre-treated with Ag490 or Stattic for 12h and then treated as above. RNA was 
isolated and subjected to qRT-PCR for Cxcl9, Cxcl10, Ccl5 and iNOS. C, On the medium remained after 
treatment as in B, ELISA for Cxcl19 was performed. p<0.05 was considered significant.  
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is limited information about potential signal integration between IFNγ and TLR4 in non-
immune cells. Our results suggest that also in ECs, VSMCs and proximal tubular cells, crosstalk 
between IFNγ and LPS results in amplification of genes related to inflammation.  
 
Several mechanisms have been suggested by which the IFNγ and TLR4 pathway can 
cooperate. Experiments performed in macrophages revealed that in addition to IFNγ also TLR4 
stimulation triggers phosphorylation of STAT1 at tyrosine 701. LPS-mediated phosphorylation 
of STAT1 is utilized by the induction and subsequent autocrine activities of type I IFN (IFNβ) 
and as such this crosstalk is protein synthesis-dependent. Indeed, we observed STAT1 
phosphorylation upon treatment with LPS, which was blocked in the presence of 
cyclohexamide, the substance that inhibits protein synthesis (data published here [161]).  
One of the models explaining functional cooperation between IFNγ and LPS in macrophages 
was a mechanism suggested by Schroder et al. [120]. In this model the transactivator ability of 
STAT1 is highly amplified upon treatment with both IFNγ and TLR ligands. Similarly to 
macrophages and splenocytes (Fig. 2-1), treatment of ECs and VSMCs with IFNγ followed by 
LPS resulted in increased STAT1 phosphorylation as compared to both factors alone. 
Stimulation with IFNγ followed by LPS revealed a synergistic amplification of Cxcl9, Cxcl10, 
Ccl5, and an important contributor of oxidative stress, Nos2 (iNOS), in vascular cells as well as 
in proximal tubular cells. This coincided with increased STAT1 phosphorylation in ECs and 
VSMCs. Taken together, our results suggest that also in vascular cells increased STAT1 
phosphorylation and thus transactivator ability is mediated by TLR-dependent expression of 
type I IFN.  
Interestingly, pretreatment of proximal tubular cells with IFNγ followed by LPS did not result 
in amplified phosphorylation of STAT1 (Fig. 2-4). Wen et al. suggested the importance of 
serine 727 phosphorylation in maximal STAT1 activity [54]. Thus we verified whether this 
phenomenon occurs in proximal tubular cells. We observed increased serine phosphorylation 
of STAT1 upon treatment with IFNγ that was not changed upon addition of LPS. Together with 
the lack of response to LPS, these results suggest the existence of other, phosphorylation-
independent and tissue-specific mechanisms that are involved in functional cooperation 
between IFNγ and TLR4 in proximal tubular cells. One mechanism which may explain this 
amplification may be related to increased expression of STAT1 and other transcription factors 
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that are STAT1-dependent, e.g. IRF1. Indeed, promoter analysis predicted the presence of 
binding sites for NFκB and IRF1 in the regulatory regions of Cxcl9, Cxcl10, Ccl5 and Nos2  
(Fig. 2-7). Expression analysis of IRF1 confirmed a higher abundance of IRF1 and STAT1 upon 
treatment with IFNγ that was not affected by LPS (Fig. 2-8). Because phosphorylation of STAT1 
does not seem to play a role, either increased interaction of STAT1 or IRF1 or activity of NFκB 
may contribute to synergistic amplification. We examined the expression of TNFα to verify 
whether the transcriptional activity of NFκB is increased during stimulation with both stimuli. 
Literature data indicate that abundance of this cytokine depends directly on the activity of 
NFκB but not STAT1 [143]. We observed induction of TNFα expression upon LPS stimulation 
that was not significantly different from the expression observed in samples treated with IFNγ 
and LPS. These data suggest that not the transcriptional activity of NFκB but increased 
expression of IRF1 and STAT1 upon IFNγ stimulation contribute to the synergistic amplification 
of proinflammatory mediators in tubular cells. A higher abundance of STAT1 and IRF1 may 
lead to increased sensitivity to LPS and, as a consequence, to amplification of Cxcl10, Ccl5 and 
Nos2.  
Recently, a new model which may also explain the mechanism of signal integration between 
IFNγ and TLR4 was proposed [85]. In this model STAT1 is considered to be a factor that 
initiates chromatin remodeling. IFNγ-activated STAT1 affects histone acetylation and thus 
causes increased and prolonged recruitment of additional transcription factors and 
polymerase II after TLR4 stimulation. Further studies are necessary to clarify the mechanism 
contributing to signal integration in proximal tubular cells. 
The transcriptional regulation of proinflammatory mediators has shown to involve several 
transcription factors, including STAT1, NFκB or IRFs [129, 136, 137, 162-166]. Indeed, in silico 
promoter analysis predicted the presence of binding sites recognized not only by STAT1 but 
also other factors such as NFκB or IRF1 (Fig. 2-7). Our experiments suggest that cooperation 
between STAT1, IRF1 and other transcription factors is crucial for synergistic amplification of 
Cxcl9, Cxcl10, Ccl5 and Nos2 also in vascular cells as well as in tubular cells. Expression of Nos2 
was highly amplified upon combined treatment in all investigated cells. Additionally,  
this result was confirmed by measurements of nitrite in VSMCs (Fig. 2-3 C). The promoter of 
the Nos2 gene contains regulatory sequences recognized not only by NFκB but also by STAT1 
homodimer complexes, (gamma interferon-activated site, GAS) and IRFs [167-170] (Fig. 2-7). 
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In addition, recently published data pointed to the important role of the ISGF3 complex 
(containing STAT1-STAT2-IRF9) involved in the regulation of iNOS expression upon 
concomitant stimulation with type I IFN and the agonist of pathogen recognition receptors 
[164]. In macrophages, combined stimulation with IFNγ and LPS or TNFα results in increased 
upregulation of NO [171]. Foremost, this upregulation is IRF1-dependent, thus suggesting 
cooperation between STAT1, IRF1 and NFκB in response to IFNγ and LPS [169]. Taking into 
consideration the fact that the abundance of Nos2 after stimulation with IFNγ was barely 
detectable, it is tempting to speculate that transcription of iNOS is rather dependent on the 
ISGF3 complex than on functional cooperation between STAT1 homodimers and IRF1.  
 
Similarly to iNOS, expression of Cxcl10 was synergistically increased in ECs and VSMCs treated 
with IFNγ followed by LPS, and was ameliorated in the presence of Ag490 or stattic. This result 
correlates with a predominant STAT1-dependent mechanism engaged in the integration of 
both stimuli. Indeed, literature data suggest that, like iNOS, maximal expression of Cxcl10 
requires activation of both pathways. However, in contrast to Nos2 transcription, synergistic 
amplification of Cxcl10 requires cooperation between STAT1 and IRF1, but not NFκB [136, 163, 
172]. Importantly, experiments performed in our laboratory revealed that also in the vascular 
cells, transcription of Cxcl10 is protein synthesis-dependent [161]. Because expression of IRF1 
can be triggered not only by IFNγ but also by LPS, it is very likely that a similar IRF1-dependent 
mechanism mediates expression of Cxcl10 in VSMCs and ECs upon treatment with IFNγ and 
LPS. However, in tubular cells, LPS stimulation did not result in a statistically significant 
increase in IRF1 expression. Thus it is very likely that NFκB plays a more substantial role in 
regulating Cxcl10 abundance in tubular cells.  
In contrast to iNOS and Cxcl10, whose expression pattern was similar for all investigated cell 
types, abundance of Cxcl9 and Ccl5 was different between cells isolated from spleens and 
non-immune cells. While there was strong transcriptional activation of Ccl5 and Cxcl9 upon 
combined treatment in vascular cells and tubular cells, we could not detect a synergistic effect 
of IFNγ and LPS in murine splenocytes (Fig. 2-1). This phenomenon can be explained by the 
partially different transcriptional regulation of specified genes in myeloid and lymphoid cells. 
Literature data suggest that in immune cells, expression of Cxcl9 and Ccl5 is controlled by 
tissue-specific transcription factors [144, 173]. These factors are often present in the latent 
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stage, therefore additional stimulation with extracellular ligands (e.g. IFNγ or LPS) is not 
mandatory for efficient upregulation of downstream targets; for example, IFNγ-mediated 
transcription of Cxcl9 is dependent on cooperation between STAT1 and tissue-specific 
transcription factor Pu.1 in myeloid cells [173].  
 
Although the patterns of expression upon combined treatment are similar for Cxcl9 and Ccl5, 
treatment with LPS or IFNγ alone indicates different regulatory mechanisms. As opposed to 
Cxcl9, whose expression is IFNγ-dependent, transcription of Ccl5 relies rather on activation of 
TLR4. Despite the fact that IFNγ stimulation leads to expression of Ccl5 in macrophages [174], 
in other cell types, e.g. synovial fibroblasts, mesothelial cells, alveolar epithelial cells or 
peritoneal fibroblasts, stimulation only by IFNγ is insufficient for expression of Ccl5 [175-179]. 
This is in line with our observations for vascular and tubular cells. Indeed, literature data 
suggest the importance of NFκB in the regulation of Ccl5 expression [137, 178].  
To obtain further evidence for the role of the STAT1 and JAK/STAT pathway in crosstalk 
between IFNγ and LPS, we used inhibitors that are known to affect either JAK2 (Ag490)  
or STAT1/STAT3 (stattic) [180]. Expression of STAT1-dependent genes was only partially 
attenuated upon stimulation with the antagonist of the JAK/STAT pathway (Fig. 2-7). Ag490 is 
an inhibitor of the JAK2 kinase which participates in the formation of active STAT1 dimers 
upon stimulation with IFNγ. Indeed, Ag490 can effectively block the IFNγ response, as samples 
treated only with IFNγ did not express STAT1-dependent genes (data not shown). However, 
during the crosstalk, STAT1 phosphorylation is partially mediated through the activity of JAK1 
and Tyk2 kinases. This mechanism could explain only the partial inhibition of STAT1 action by 
Ag490 and further indicates the importance of the autocrine activities of type I IFN (IFNβ).  
Although stattic was considered as a specific inhibitor of STAT3, experiments performed in our 
laboratory revealed that it can also antagonize STAT1 phosphorylation upon stimulation with 
type I interferon [180, 181]. However, experiments based on IFNγ stimulation, which is a far 
more powerful activator of STAT1, revealed only partial efficacy of stattic. This suggests that 
STAT3 is indeed a primary target of stattic and that partial inhibition of STAT1 action is rather 
a side effect of stattic, as both STATs share structural similarities. Importantly, both inhibitors 
can affect STAT1 and STAT3 action. Thus, we cannot exclude the role of STAT3 in upregulation 
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of these genes. Further experiments with STAT1- and STAT3-deficient animal models are 
mandatory.  
 
Our results presented in this section as well as those published in the American Journal of 
Physiology – Cell Physiology [161] provide further evidence for the crosstalk between IFNγ and 
TLR in ECs, VSMCs and proximal tubular cells. Although the mechanisms of transcription  
of genes prone to synergistic amplification may vary in detail, one common feature is the 
involvement of STAT1 and IRF1 in the regulation of amplified genes.  
 
Similarly to splenocytes, stimulation with IFNγ and TLR4 in ECs and VSMCs resulted in 
augmented STAT1 phosphorylation and increased expression of the chemokines Cxcl9, Cxcl10, 
Ccl5 and Nos2. Inhibition of JAK2 (Ag490) or STAT1 phosphorylation (stattic) partially 
prevented this effect. In proximal tubular cells it was not augmented STAT1 phosphorylation 
but rather increased abundance of IRF1 that contributed to the synergistic amplification.  
 
Altogether, STAT1 and IRF1 could potentially represent a novel target of therapeutic 
intervention that would have a crucial role in mediating the interplay between damaged organ 
and host immunity in order to control progression of inflammation mediated by IFNγ and TLR4.  
Fig. 2-10. STAT1 as a central point 
of crosstalk between IFNγ and TLR4 
induced pathways. Treatment with 
IFNγ leads to increased expression 
of STAT1 and STAT1-dependnet 
transcription factor that participate 
in the TLR4 signaling - IRF1. 
Increased STAT1-dependent 
expression of the IRF1 and their 
subsequent collaboration with other 
transcription factors resulted in 
synergistic amplification of Nos2, 
Cxcl10, Cxcl9 and Ccl5. 
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Chapter 3 
STAT1 and IRF8 orchestrate IFNγ and LPS-mediated signal integration in the 




A variety of diseases, including those which affect the cardiovascular system, have 
pathophysiological important role of the immune component. Atherosclerosis is a type of 
arteriosclerosis in which the function of the artery is affected by the accumulation of fatty 
plaques and cholesterol in the vessel wall. Recent studies have provided evidence for the 
crucial role of inflammation in all stages of the disease, starting from early endothelial cell (EC) 
dysfunction and altered contractility of vascular smooth muscle cells (VSMCs) through 
recruitment of blood leukocytes to the injured vascular wall and, ultimately, thrombus 
formation in the lumen [11, 182, 183]. Interferon (IFN)γ is a pivotal mediator of innate and 
adaptive immunity. Since the discovery that IFNγ is highly expressed in lesions, its role in 
atherosclerosis has been broadly studied [63, 68]. IFNγ mediates its own action through 
activation of the JAK/STAT pathway. Binding of this cytokine to IFNGR receptors leads through 
phosphorylation and homodimer formation to transcriptional activation of the protein called 
the signal transducer and activator of transcription (STAT) 1. Recently obtained data indicate 
that STAT1 is not only involved in signal transduction upon treatment with IFNγ but also 
contributes to the biological response to different toll-like receptors (TLRs). TLRs are  
a family of innate immune pattern-recognition receptors which recognize pathogen- and 
damage-associated molecular patterns, e.g. lipopolysaccharide (LPS), or heat shock proteins 
(HSP), and play an important role in the progression of atherosclerosis [184]. Activation of 
TLR4 signaling triggers the induction of various target genes that include those encoding type I 
IFNs, chemokines and cell surface molecules [150]. Some of these genes are regulated 
secondary to LPS-induced IFNβ which, after secretion, binds to the type I IFN receptor to 
activate gene expression in a STAT1-dependent manner [185]. As such, STAT1 has been 
identified as an important mediator in the biological response to different TLRs, including 
TLR4. Signal integration between IFNγ and TLRs has been described especially in immune cells 
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and was related to host defense against pathogens and injury. Stimulation of macrophages 
and dendritic cells with IFNγ and LPS was mandatory for efficient expression of 
proinflammatory mediators [120, 121]. Moreover, STAT1 was identified as an important 
mediator of this crosstalk [118, 128]. In addition to STAT1, also STAT1 target genes which 
belong to the family of interferon regulatory factors (IRF) have been involved in signal 
integration between IFNγ and LPS; for instance, IRF8, which was thought to be immune 
specific, was identified as being involved in the synergistic induction of proinflammatory 
genes, such as Il1, Il6, Il12, TNFα and Ccl5. [115, 144]. These data imply that STAT1 and the 
IRFs coordinate the crosstalk between IFNγ and TLRs and therefore positively regulate 
inflammation. Our recent observations suggest that the mechanism that was previously 
identified in immune cells is also present in cells that build the vascular wall [161]. Augmented 
STAT1 phosphorylation was associated with increased expression of chemokine CXCL10 and 
the adhesion molecule ICAM-1. We could observe increased adhesion of U937 leukemia cells 
to ECs in a STAT1-dependent manner [161].  
 
In this chapter we provide results to further support the hypothesis that activated STAT1 
together with downstream-regulated IRFs serve as a platform for increased TLR4 signaling in 
cells from the vasculature, thus resulting in the expression of genes related to inflammatory 
processes. We conducted expression profiling on VMSCs in order to identify sets of STAT1 
target genes prone to synergistic amplification. We identified sets of new, potentially 
interesting targets. We showed for the first time that transcription factor IRF8 is also 
expressed in the vessel wall and may be involved in the progression of inflammatory response. 
Moreover, by performing immunohistochemistry on human data sets we provided further 
evidence for the importance of the above-mentioned signaling in human atherosclerosis.  
 
Material and Methods  
 
Cell culture experiments  
WT mice (strain background C57BL/6) were obtained from Charles River Laboratories 
(Sulzfeld, Germany). STAT1-/-and IRF8-/- mice (both C57BL/6 background) were kindly provided 
by Thomas Decker and Carol Stocking, respectively [186], TLR4-/- (C57BL/6 background) were 
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bred in our own facility [187]. Primary murine Vascular Smooth Muscle cells (VSMCs) were 
isolated from WT or STAT1-/- or IRF8-/- mice by enzymatic digestion [188] in a solution 
containing collagenase type II 1mg/ml, soybean trypsin inhibitor 1mg/ml (Life Technologies, 
Carlsbad, USA), elastase 0.744u/ml (Sigma-Aldrich, Missouri, USA) in HBSS (Life Technologies). 
Isolated aortas from 2 mice were cleaned from perivascular fat and predigested for 10min. 
Subsequently adventitia was removed, aortas were cut lengthwise and intima was removed 
by gentle scraping. Next aortas were enzymatically digested for 1h at 37˚C. After digestion 
aortas were passed through 100µm cell strainer (BD, Heidelberg, Germany) and left 
undisturbed on 3 wells of a 48 well plate for 1 week. Until passage number 3 cells were 
cultivated in DMEM medium (PAA, Linz, Austria) containing 4.5mg/l Glucose, 2mM L-Glu, 
supplemented with 100U/ml penicillin and 100μg/ml streptomycin and 20% FBS (PAA). After 
3rd passage 10% FBS was used. Human Microvascular Endothelial Cells (HMECs) obtained from 
Centers for disease control and prevention (Atlanta, GA, USA) were cultivated in MCDB-131 
(Life Technologies) medium containing 10% FBS (PAA), 100U/ml penicillin, 100μg/ml 
streptomycin, 0.01µg/ml EGF, 0.05µM hydrocortisone, 2mM L-glutamine (PAA). On the day 
before an experiment for both cell types full medium was exchanged into medium containing 
2% serum. Afterwards cells were treated with 10ng/ml of IFNγ (Life Technologies) and/or 
1µg/ml of LPS (Sigma).  
 
RNA isolation and real-time PCR 
Total RNA was isolated from VSMCs and HMECs using RNAeasy Mini Kit (Qiagen, Hilden, 
Germany) together with DNAse digestion step according to the manufacture’s protocol. 
Complementary DNA was synthesized using iScript cDNA Synthesis Kit (Bio-Rad, Hercules, 
USA), according to manufacturer’s protocol. Quantitative reverse transcriptase PCR (qRT-PCR) 
was performed using SSoFast Evagreen (MyiQ ICycler, Bio-Rad). Forward and reverse primers 
are depicted in Table 3-1. The 2-ddCt method was applied for quantification [155]. Fold change 
in the target gene were normalized to GAPDH and relative to the mean expression at 
untreated sample. The results are expressed as fold of control from at least 3 independent 
assays. Regular PCR was performed using AmpliTaq Gold 360 DNA polymerase kit (Life 
Technologies) together with dNTP mix (Sigma). Bands were visualized by staining gels with 
peqGreen (Peqlab).   
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Table 3- 1. Primer sequences used in experimental procedures 
Gene Name Forward Reverse 
Gapdh TCGGTGTGAACGGATTTGGC TTTGGCTCCACCCTTCAAGTG 
Irf8 GCAGGATGTGTGACCGGAAC CCACCTCCTGATTGTAATCCT 
Ccl5 (Rantes) CGCACCTGCCTCACCATAT CACTTCTTCTCTGGGTTGGC 
Cxcl10 TCATCCCTGCGAGCCTATCC GGAGCCCTTTTAGACCTTTTT 
Cxcl9 CTGCCATGAAGTCCGCTGTTCT TCCCCCTCTTTTGCTTTTTCTT 
Ccl12 AGCTACCACCATCAGTCCTCA CAAGGATGAAGGTTTGAGACG 




 GAPDH _human CAACTGCTTAGCACCCCTGG CAGGTCAGGTCCACCACTGA 
IRF8_human GGGAGAATGAGGAGAAGAGCA CCGCACTCCATCTCTGTAACT 
 
Microarray analysis  
VSMCs from WT and STAT1-/- were treated as described in Fig. 1. RNA from control and 
treated samples was isolated and labeled according to Illumina® TotalPrep™ RNA 
Amplification Kit (LifeTechnologies, CA). Standard Illumina Expression BeadChip MouseRef-8v2 
(Illumina, SA) hybridization protocol was used to obtain the raw data. Chips were scanned 
using HiScanSQ system. The complete data of the Illumina Expresion BeadChip analysis can be 
found at the NCBI GEO, with the accession number GSE49519. The average gene expression 
signals from 3 independent biological experiments were taken for statistical testing. Only 
genes from treated samples with detection p-value <0.05 were chosen for further analysis. 
Background subtraction and quantile normalization were used to obtain statistically significant 
( p<0.05 ) at least 2-fold upregulated genes. Genes which expression after co-treatment was at 
least 2-fold higher upon stimulation with IFNγ + LPS as compared to the sum of the 
treatments with both factors alone were considered as amplified. Promoters for amplified 
STAT1 dependent genes were screened using GENOMATIX software 
(http://www.genomatix.de/) [160]. The promoter regions from -1000 to +100bp were 
searched for binding sites (V$IRF1.01 V$ISGF3G.01 V$ISRE.01 V$ISRE.02 V$CREL.01 
V$NFKAPPAB.01 V$NFKAPPAB.02 V$NFKAPPAB65.01 V$STAT.01 V$STAT1.01 V$STAT1.02)  
or models with core similarity at least 0.85.  
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Western blot analysis 
Total IRF8, STAT1 (Santa Cruz, sc6058, sc346), GAPDH and phosphorylated STAT1  
(Cell Signaling, 5174s, 9171l) were determined by western blotting in VSMCs and HMECs. 
After treatment cells were homogenized in a Ripa lysis buffer (Sigma-Aldrich) containing 
phosphatases and proteases inhibitors (Roche). Protein concentration was determined using a 
bicinchoninic acid protein assay kit (Thermo Fisher Scientific). 40µg of protein per lane was 
loaded and resolved by SDS-poly-acrylamide gel electrophoresis (PAGE) under reducing 
conditions. Proteins were transferred onto PVDV (Millipore, Billerica, USA) membrane. After 
incubation with primary and horseradish peroxidase-conjugated secondary antibodies (Santa 
Cruz), immunoreactivity was detected by adding Luminata Forte Western Substrate (EMD 
Millipore) and measured by INTAS imaging system (Intas, Goettingen, Germany). 
 
Cytokine detection ELISA 
Expression of murine Cxcl10, Ccl5 (Peprotech, Hamburg, Germany) as well as Cxcl9 (Sigma) 
was performed on medium remained after treatment of VSMCs using sandwich ELISA tests 
according to the manufacturer’s instructions.  
 
Measurement of nitric oxide (NO) 
VSMCs were treated as depicted in cell experiment section. After treatment medium was 
refreshed and cells were cultivated for further 24h. Subsequently medium was collected and 
100ul was used to measure amount of NO by Griess diazotization reaction. Medium was 
incubated with freshly prepared solution containing 1% sulfanilamide 5% HCl, 0.1% aqueous 
solution of 2-(1-Naphthylamino)ethylamine dihydrochloride (Sigma). After 10min incubation 
OD at 560mm was measured and compared to the standard curve. 
 
Histology and immunohistochemistry 
Histological analyses and immunohistochemistry were performed on representative sections 
(2-3 µm) of formalin fixed in paraffin embedded tissue samples from six human carotid 
atherosclerotic lesions and four healthy controls. Hematoxylin-Eosin (HE) and Elastica-van-
Gieson (EvG) staining were performed in order to assess sample morphology.  
For characterisation of the cells within atherosclerotic plaques, specimens were treated with 
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antibodies against vascular smooth muscle cells (smooth muscle myosin heavy chain 1 and 2 
(SM-M10), rabbit polyclonal, dilution 1:4.000 (Abcam, ab81031) and endothelial cells  
(anti-CD31, mouse monoclonal, clone JC70A, dilution 1:100; Dako).  
For the detection of specific cytokines, CXCL9 (MIG) and CXCL10 (IP10), as well as the 
phosphorylated transcription factor STAT1, following primary antibodies were used: rabbit 
polyclonal anti-MIG (Abcam, ab9720; dilution 1:500), rabbit polyclonal anti-IP10 (Abcam, 
ab47045; dilution 1:200), and rabbit monoclonal phospho-Stat1 (Cell Signaling, 9171l; dilution 
1:400). All antibodies were first optimised on tonsil using different dilutions, staining 
conditions and with or without blocking. Optimal results were achieved by blocking anti-MIG 
and anti-phospho-Stat1 with goat serum, anti-IP10 without the blocking procedure.  
Following incubation with primary antibody visualisation was performed by peroxidase/DAB 
ChemMate Detection Kit according to the manufacturer’s instruction (biotinylated goat  
anti-mouse/anti-rabbit secondary antibody; Dako). 
 
Histology and fluorescent immunohistochemistry 
Histological analyses and fluorescent immunohistochemistry were performed on 
representative sections (2-3 µm) of formalin fixed, paraffin embedded human carotid artery 
tissue specimens obtained from patients with high-grade carotid artery stenosis (>70%) after 
carotid endarterectomy in the Department of Vascular and Endovascular Surgery (Klinikum 
rechts der Isar, Technical University Munich). Immunostaining war performed using antibodies 
to detect VSMCs (mouse monoclonal anti-SMA, HHF35, dilution 1:200; Dako, Glostrup, 
Denmark), endothelial cells (mouse monoclonal anti-CD31, JC70A, dilution 1:100; Dako), 
mouse monoclonal macrophages/monocytes (anti-CD68, KP1, dilution 1:1000; Dako), 
leukocytes (rabbit polyclonal anti-CD45, dilution 1:200; Dako) and IRF8 (goat polyclonal 
antibody, dilution 1:500; Santa Cruz Biotechnology, Santa Cruz, CA, USA). Primary antibodies 
(combined in the following way: CD68/IRF8, CD45/IRF8, CD31/IRF8, SMA/IRF8) were 
incubated over night at 4°C, and visualized by secondary antibody incubation for one hour 
(Alexa Fluor 488-conjugated goat-anti-mouse IgG, Alexa Fluor 488-conjugated donkey-anti-
rabbit, or Cy3-conjugated donkey-anti-goat, dilution 1:200; Dianova, Hamburg, Germany). 
VECTASHIELD mounting medium containing DAPI fluorescence dye for staining of the cell 
44 | P a g e  
 
nuclei was used (Axxora, Loerrach, Germany). Images were recorded using a Leica microscope 
DM4000B (Leica Microsystems, Wetzlar, Germany). 
 
Migration assay 
Migration assay was performed according to Guo et al [189]. Briefly, 106 of isolated red blood 
cells depleted splenocytes were loaded into the upper chamber of Transwell 24-well plates 
(Corning). The bottom chamber was filled with 600ul of the medium collected after treatment 
of VSMCs with LPS, IFNγ or IFNγ and LPS. After incubation for 3h at 37˚C, migrated cells were 
stained with CD45FITC and CD3APC antibody (Miltenyi Biotec 130091609, 130092977) and 
analyzed by flow cytometer (Miltenyi Biotec).  
 
Ex vivo experiments and contractility studies 
Cleaned form perivascular fat aortas were cut into 2mm long rings (for myograph) and placed 
in DMEM medium containg 2% FBS (Sigma). Next, aortas were treated with 10ng/ml of IFNγ 
and/or 1µg/ml of LPS. Vascular contractility studies were performed according to the 
technique described by Mulvany et al. [190]. After treatment, 2mm long rings were mounted 
in a 4-channel myograph (620M, Danish Myo Technology, Denmark) in the organ chamber 
filled with physiological saline solution (PSS; 118.99mM NaCl, 4.69mM KCl, 1.17mM 
MgSO4*7H2O, 1.18mM KH2PO4, 2.5mM CaCl2*2H2O, 25mM NaHCO3, 0.03mM EDTA, 5.5mM 
Glucose). During the experiment PSS buffer was aerated with carbogen (95% O2+ 5%CO2). 
After calibration, vessels were pre-streched to obtain optimal passive tension. Next, vascular 
functions were analyzed. Contractility was evaluated by substitution of PSS buffer for high 
potassium physiological saline solution (KPSS; 74.7mM NaCl, 60mM KCl, 1,17mM 
MgSO4*7H2O, 1,18mM KH2PO4, 1.6mM CaCl2, 14.9mM NaHCO3, 0.026mM EDTA, 5.5mM 
Glucose). For testing viability, vessels were subjected to noradrenaline-induced constriction 
followed by acetylcholine-induced dilation (Sigma). After washing out with PSS buffer and 
resting for 15 minutes, noradrenaline dose-response curves was performed. Noradrenaline 
was used in stepwise increased, cumulative concentration ranging from 10-11 to 10-6 mol/L. To 
study vasodilatation, sodium nitroprusside (Sigma) was used in concentrations from 10-10 to  
10-5 mol/L.  
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Statistical Analysis  
Data are presented as mean ± SEM of at least 3 experiments ±SEM. For comparisons between 
more than two groups one-way ANOVA with Tukey post-hoc test was used. In all other 
experiments comparing two groups, Student’s t-test was used. A probability value (p) <0.05 
was considered statistically significant (GraphPad Prism ® 5.0). In contractility studies,  




In SMCs signal integration between IFNγ and LPS is TLR4 and STAT1-dependent. 
Our observations presented in previous chapter suggest that both in HMECs and VSMCs, 
STAT1 orchestrates a platform for cross-talk between IFNγ and TLR4. This resulted in 
augmented STAT1 phosphorylation and increased expression of the genes like chemokine 
Cxcl10 and iNOS (Nos2). In addition, treatment with fludarabine which thought to be an 
specific STAT1 inhibitor, resulted in ameliorated expression of Cxcl10 [161, 191, 192]. 
However, recently obtained data in our laboratory indicate that fludarabine is not an STAT1 
specific inhibitor and do affects other STATs [180]. Thus, to confirm that this mechanism is 
STAT1 dependent, VSMCs were isolated from WT, STAT1-/- and TLR4-/-mice and treated as 
depicted in Fig. 3-1. Indeed, we could observe synergistic mRNA amplification of Cxcl10  
(Fig. 3-1 A, left panel) and iNOS (Fig. 3-1 A, right panel) in WT-VSMCs upon combined 
treatment, compared with IFNγ or LPS alone. Synergistic amplification in WT-VSMCs was 
present at the mRNA level as well as at the protein level for Cxcl10 (Fig. 3-1 B, left panel). 
Griess reaction which measures indirectly activity of the nitric oxide synthase, reflected results 
obtained at mRNA level for iNOS in WT-VSMCs (Fig. 3-1C). In contrast, this IFNγ and LPS-
induced signal integration in Cxcl10 and iNOS gene expression was dramatically abrogated in 
STAT1-/-and TLR4-/--VSMCs (Fig. 3-1 A), which coincided with Cxcl10 protein levels and amount 
of the nitrite in the medium (Fig. 3-1B, 3-1 C).  
These results further confirm importance of STAT1 in crosstalk between both pathways. 
Interestingly, whereas TLR4 deficient VSMCs failed to express Cxcl10 and iNOS upon 
stimulation with LPS, STAT1-/--VSMCs not only did not express both genes upon treatment 
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with IFNγ but also treatment with LPS alone resulted with blunted response (Fig. 3-1 A and B). 
Presented results allow us to suggest that STAT1 is not only involved in the IFNγ signal 
transduction and crosstalk between JAK/STAT and TLR4 but also participates in response to 











Fig. 3-1. Cxcl10 and iNOS amplification by IFNγ and LPS is STAT1 dependent. A, VSMCs were 
treated with 10ng/ml IFNγ for 8h or with 1ug/ml of LPS for 4h or with IFNγ for 4h followed by IFNγ 
and LPS for additional 4h. RNA was isolated and qRT-PCR for Cxcl10 and iNOS using Gapdh as 
internal control was performed. B, Cells were treated as in A. On the medium remained after 
treatment ELISA for Cxcl10 was performed. C, After treatment medium was refreshed and cells were 
cultivated for further 24h. 100µl was used to measure nitrite. Data represent means of at least 3 
independent biological experiments ±SEM and p<0.05 was considered as significant. 
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Table 3-2. Genes prone to synergistic amplification upon stimulation with IFNγ and/or LPS and their promoter analysis 
The Table introduces genes that expression is at least 2-fold higher upon stimulation with IFNγ+LPS as compared to the sum of the treatments with both factors alone 
















STAT_NFκB IRF_NFκB ISRE STAT NFκB Cluster 
Cxcl9 150.73 20.25 15.46 2643.50 0.93 9.87 9.52 x - - - - A 
Cxcl10 343.62 665.68 2.25 2273.44 0.47 119.63 66.53 x x - - -  
Rsad2 22.91 209.45 2.19 509.05 1.53 2.93 2.71 - - x x x  
Gbp5 53.48 82.66 2.85 388.28 1.28 65.64 72.68 x - x x x 
Batf2 134.37 3.23 2.29 314.46 5.35 5.10 8.31 x - x x x B 
Ubd 21.54 3.38 13.11 326.57 0.80 4.71 6.44 x - x - - 
Cd74 37.66 2.93 5.09 206.50 0.78 8.01 8.24 x x - - - 
Fam26f 43.02 13.60 2.42 137.16 0.95 13.25 13.07 - - x x - 
Serpina3g 24.76 13.36 2.59 98.56 2.12 5.12 7.79 x - x - - 
Ccl5 2.14 249.59 2.04 512.54 0.83 64.48 52.22 x x - - - C 
Tnfaip2 6.52 45.55 2.27 118.00 1.14 28.83 27.04 x - - - - 
Cd40 1.03 15.21 7.83 127.14 0.70 14.09 14.14 - - x x x 
Lincr 1.07 21.38 4.84 108.75 1.16 29.33 25.78 - - x x x 
Nos2 0.71 33.99 2.08 72.15 0.73 22.52 24.13 x x - - - 
Ccrl2 4.18 8.16 3.72 45.93 0.76 5.87 4.65 x - x - - D 
Mx1 3.10 12.73 2.49 39.41 0.91 1.68 1.18 x - x - - 
Has1 1.40 8.71 2.16 21.84 1.17 11.64 14.92 - - - x x 
Oasl1 1.80 7.61 2.13 20.10 1.03 1.45 1.83 - - x - x 
MCP-2 6.12 3.75 3.83 37.77 5.21 44.53 58.31 - - - x - 
Atf3 3.73 2.47 3.27 20.29 1.21 4.34 3.96 - - - x x 
Ifi205 5.39 2.99 2.28 19.10 0.64 4.24 4.81 - - x x - 
Upp1 2.67 2.37 2.87 14.45 1.17 2.25 3.53 x - x - - 
Tnfrsf11a 0.20 5.87 2.12 12.85 1.46 7.44 12.33 x - - - - 
Irf8 6.13 0.41 2.98 19.51 1.40 1.03 0.77 x - - - - E 
MCP-5 1.05 0.32 8.65 11.86 0.69 0.59 0.78 - - x x x 
Sectm1a 1.21 0.27 2.45 3.62 0.30 0.37 1.16 x - x - - 
Gja4 1.25 0.83 4.50 9.35 0.55 0.37 0.27 - - - - x 
Egr2 1.74 1.96 1.98 7.32 0.98 2.31 1.73 x - - - - 
Itpk1 1.12 1.29 2.19 5.29 0.86 0.97 1.30 - - - x x 
Etsrp71 0.48 0.83 2.43 3.18 1.39 0.96 0.96 - - - x x 
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Transcriptional responses in IFNγ and LPS treated VSMCs depend on STAT1, NFκB and 
IRF and predict pro-atherogenic phenotype. 
To examine how pretreatment of VSMCs with IFNγ affected the response to LPS at a genome 
wide level, and in particular whether distinct sets of STAT1-dependent genes could be 
identified, we performed expression profiling. Complete results of microarray can be found at 
the NCBI GEO, with the accession number GSE49519. We aimed to identify genes that similar 
to Cxcl10 and iNOS were synergistically affected by the interactions between IFNγ and LPS. We 
selected genes which expression was at least 2 fold higher upon stimulation with IFNγ + LPS as 
compared to the sum of the treatments with both factors alone.  
 
Table 3-3. Gene ontology classification of synergistically amplified genes 
Term ID Description Frequency log10 p-value Uniqueness Dispensability 
GO:0051707 response to other organism 0.01 -10.10 0.56 0.00 
GO:0009607 response to biotic stimulus 0.01 -9.62 0.66 0.40 
GO:0006952 defense response 0.01 -8.91 0.63 0.41 
GO:0002376 immune system process 0.01 -7.61 0.97 0.00 
GO:0071345 cellular response to cytokine 
stimulus 
0.00 -6.87 0.52 0.32 
GO:0006950 response to stress 0.04 -6.59 0.61 0.50 
GO:0006955 immune response 0.01 -6.26 0.41 0.39 
GO:0006954 inflammatory response 0.00 -5.91 0.68 0.49 
GO:0045071 negative regulation of viral 
genome replication 
0.00 -5.04 0.76 0.47 
GO:0009611 response to wounding 0.00 -4.93 0.68 0.53 
 
Table 3-2 presents 30 genes prone to signal integration. Functional analysis of the genes listed 
in Table 3-2 revealed substantially enriched gene ontology terms that are related to biological 
functions involved in host defense, immune response, inflammatory response, cytokine 
response, response to stress and to wound healing (Table 3-3). Among them were genes 
involved in chemotaxis like Cxcl9 (fifteen fold higher after combined treatment), Cxcl10, Ccl5, 
Ccl12, Ccl8, Ccrl2, Cxcl10, adhesion molecules Cd40, Cd74, and the antiviral and antibacterial 
response genes Irf8, Rsad2, Mx1, Oasl1, Gbp5, Nos2, Batf2 and Tnfrsf11a. Depending on their 
characteristic response pattern in WT-VSMCs, we could divide genes listed in Table 3-2 into 
five groups (Fig. 3-2).  
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First group consist of Cxcl9, Cxcl10, Rsad2 and Gbp5. These genes were highly expressed upon 
treatment with IFNγ and LPS alone and highly amplified upon combined treatment (Cluster A 
in Table 3-2 and Fig. 3-2 A). Genes form the second group (Batf2, Ubd, Cd74, Fam26f and 
Serpina3g) responded moderately to LPS, were highly expressed upon treatment with IFNγ 
and synergistically amplified upon combined treatment (Cluster B in Table 3-2 and Fig. 3-2 A). 
Alike, genes from the third group responded moderately to IFNγ, highly to LPS and were highly 
amplified upon combined treatment. This group was represented by Ccl5, Tnfaip2, Cd40, Lincr 
and Nos2 (Cluster C in Table 3-2 and Fig. 3-2 A). The fourth group of genes was represented by 
Ccrl2, Mx1, Has1, Oasl1, MCP-2, Atf3, Ifi205, Upp1 and Tnfrsf11a and displayed mild or no 
response to IFNγ, mild response to LPS, and mild amplification after combined treatment 
Fig. 3-2. Analysis of genes prone to synergistic amplification upon treatment 
with IFNγ and LPS. VSMCs from WT and STAT1-/- were treated as described in  
Fig 3-1. On RNA isolated from treated samples transcritpome profiling was 
performed. Complete results of microarray can be found at the NCBI GEO, with 
the accession number GSE49519. Genes which expression was at least 2 fold 
higher upon stimulation with IFNγ + LPS as compared to the sum of the 
treatments with both factors alone were selected for further analysis.  
A, Clustering of the synergistically upregulated genes according to their 
expression profile in WT-VSMCs. B, Heat map representing expression of the 
synergistically amplified genes in WT-VSMCs and STAT1-/--VSMCs.  
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(Cluster D in Table 3-2 and Fig. 3-2 A). Finally, we could also identify genes which showed 
minor or no response to IFNγ and LPS alone, but were highly amplified in expression after 
combined treatment [e.g., Irf8, MCP-5, Sectm1a, Gja4, Egr2, Itpk1 and Etsrp71] (Cluster E 
(Cluster D in Table 3-2 and Fig. 3-2A). Next, we compared expression profile between WT-
VSMCs and STAT1-/- VSMCs with respect to the genes listed in Table 3-2 (Fig. 3-2 B). The 
synergistic effect of combined treatment with IFNγ and LPS was no longer present in STAT1-
deficient VSMCs. As expected, lack of STAT1 resulted in lack of response to IFNγ, except Mcp-2 
(Ccl8) which expression seemed to be STAT1 independent (Table 3-2, 6.12 vs. 5.12). Although 
effect of LPS stimulation was not completely abolished in STAT1-/- VSMCs, in 50% of the genes 
listed In Table 3-2 response to LPS was ameliorated. Only expression of Mcp-2 had a different 
characteristic. STAT1-deficient VSMCs triggered accelerated expression of Mcp-2 in response 
to LPS compared with WT-VSMCs (Table 3-2, 3.75 vs. 44.53).  
Additionally, to provide in silico evidence that STAT1 is involved in the regulation of above 
mentioned genes, we searched their promoter regions for overrepresented motifs that may 
be involved in the regulation of expression (Table 3-2). Promoter analysis of the synergistically 
upregulated genes predicted the presence of STAT-NFκB and IRF-NFκB modules or 
combinations of separate ISRE, STAT or NFκB binding sites, strongly suggesting the 
cooperative involvement of NFκB, STAT1 and/or IRFs in the transcriptional regulation of all of 
these genes in response to IFNγ and LPS.  
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Signal integration between IFNγ and LPS in VSMCs leads to increased migration of  
T-lymphocytes. 
Subsequently, by performing qPCR and ELISA on selected genes involved in inflammatory 
processes, we aimed to confirm results obtained in microarray experiments (Fig. 3-3).  
 
 
Fig. 3-3. Effect of STAT1 dependent signal integration on chemokines expression. VSMCs from WT and 
STAT1-/- were treated as described in Fig 3-1. A, RNA from VSMCs was isolated and qRT-PCR transcriptase 
PCR for Ccl5, Cxcl9, Ccrl2, Ccl12 using Gapdh as internal control was performed.  
B, On the medium remained after treatment of VSMCs ELISA for Ccl5 and Cxcl9 was performed. Data 
represent means of at least 3 independent biological experiments ±SEM and p<0.05 was considered as 
significant. 
 
Indeed, combined treatment led to amplification of Ccl5, Cxcl9, Ccl12, Ccrl2 only in WT-VSMCs 
as compared to stimulation with IFNγ and LPS alone (Fig. 3-3A). Analysis of the proteins in the 
medium, reflected results obtained at mRNA level (Fig. 3-3B). In contrast response to 
stimulation in STAT1-/- VSMCs was abolished (Fig. 3-3). Next, we analyzed whether synergistic 
amplification of the genes has functional consequence. Many of the chemokines listed in 
Table 3-2 are known to be involved in chemotaxis of T-lymphocytes [193].  
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Thus, we examined the effect of IFNγ and LPS crosstalk in T-cell trafficking towards 
conditioned medium (Fig. 3-4). While the migration of CD3+/CD45+ cells towards medium of 
WT-VSMCs treated with IFNγ and LPS alone led to increase of 125% and 175% respectively, 
treatment with both IFNγ and LPS was 234%. As expected, the chemotactic response  
of splenocytes towards the conditioned medium obtained after treatment of STAT1-/--VSMCs 




Signal integration between IFNγ and LPS in aortic rings leads to abolished response to 
norepinephrine and sodium nitroprusside. 
To further confirm functional relevance of concomitant IFNγ and LPS stimulation, we verified 
expression of Cxcl9 and Cxcl10 in ex vivo stimulated aortas isolated from WT animals. Indeed 
stimulation with IFNγ followed by LPS led to synergistic amplification of Cxcl9 and Cxcl10  
(Fig. 3-5). 
Fig. 3-4. Amplification of chemokines 
expression leads to increased splenocytes 
migration. Migration assay of CD45+/CD3+ 
performed on conditioned medium 
remained after treatment of VSMCs WT and 
STAT1-/-. Data represent means of at least  
3 independent biological experiments ±SEM 
and p<0.05 was considered as significant.  
Fig. 3-5. Cxcl9 and Cxcl10 overexpression 
upon IFNγ and LPS stimulation in WT 
aortas. Isolated aortas from WT animals 
were cleaned from perivascular fat and 
placed in DMEM medium with 2% FBS. 
Next aortas were stimulated as in Fig. 3-1. 
RNA was isolated and qRT-PCR for Cxcl9 
and Cxcl10 using Gapdh as internal 
control was performed. Data represent 
means of 3 experiments ±SEM and p<0.05 
was considered as significant. 
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Among the genes that were highly amplified upon treatment with IFNγ and LPS was inducible 
nitric oxide synthase (iNOS, Nos2). Activity of iNOS was found to be crucial in regulating vessel 
function. Thus, to further evaluate physiological ramifications of our experimental conditions, 
we tested vessel function using myograph (Fig. 3-6). While treatment with IFNγ did not result 
in a significant change of the response neither to norepinephrine nor sodium nitroprusside, 
stimulation with LPS resulted in reduced response to norepinephrine in WT but also STAT1-/-. 
Moreover, treatment of the WT aortic rings with IFNγ followed by LPS, resulted in ameliorated 
contractile response to norepinephrine and dilator response to sodium nitroprusside.  
In contrast aortic rings isolated from STAT1 null mice did not reveal ameliorated response to 







Fig. 3-6. Abolished response to norepinephrine and sodium nitroprusside in aortic rings stimulated 
with IFNγ and LPS. Isolated aortic rings from WT and STAT-/- mice were incubated with 10ng/ml IFNγ 
for 8h or with 1ug/ml of LPS for 4h or with IFNγ for 4h followed by IFNγ and LPS for additional 4h. 
Next, response to norepinephrine and sodium nitroprusside was tested on the wire myograph.  
A, Response to noradrenaline in WT and STAT1-deficient mice presented as a percentage of maximal 
constriction to KPSS.*p<0.001 vs. WT control; •p<0.001 vs. WT LPS; ○p<0.001 vs. STAT1-/- control.  
B, Response to stepwise increased concentration of sodium nitroprusside. xp<0.05 vs. WT control; 
∞p<0.01 vs. WT LPS; ԏp<0.05 STAT1-/-control. Aortas isolated from 3-4 animals per group were taken. 
Two-way ANOVA test with Bonferroni post hoc test was used. 
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STAT1 activation and CXCL9 and CXCL10 expression in ECs and VSMCs from human carotid 
atherosclerotic plaques. 
To gain further insight into the role of STAT1 in atherosclerosis, we performed 
immunohistochemistry staining for phosphorylated STAT1 as well as STAT1-dependent 
chemokines, CXCL9 and CXCL10 in human advanced atherosclerotic plaques of carotid 
arteries. As it is shown in Fig. 3-7 neither phosphorylated STAT1 nor CXCL9, nor CXCL10 where 
present in carotid arteries form the control group (Fig. 3-7 A, upper row). In contrast, VSMCs 
in the lesions highly expressed phosphorylated STAT1 which was associated with expression of 
chemokine CXCL9 and to a lesser extent CXCL10 (Fig. 3-7 A, middle row). Additionally, ECs 
covering the plaque likewise showed predominant staining for phosphorylated STAT1 
associated with CXCL9, and to a lesser extent with CXCL10 staining. This result gives an 
additional proof for a pro-atherogenic role of STAT1 in vascular cells of atherosclerotic 
plaques.   
Fig. 3-7. Expression of pSTAT1, CXCL9, CXCL10 in human atherosclerotic lesions in situ. Staining of the 
sections prepared from normal human artery exhibited no presence of pSTAT1, CXCL9, CXCL10 (A, upper 
panel). In contrast, all three proteins could be detected in SM-M10 positive cells in atherosclerotic 
plaques (A, middle panel) as well as in the endothelial cells at the lumen side (B). A representative 
analysis is shown of 6 human carotid atherosclerotic lesions and 4 healthy controls. Arrows represent 
examples of positive staining. In B arrows with asterix indicate an examples of positively stained VSMCs. 
Scale bar = 100µm.  
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IRF8 is highly expressed in SMCs and ECs in response to IFNγ and LPS. 
Among, the genes which were synergistically amplified upon combined treatment with IFNγ 
and LPS was also IRF8. This transcription factor is considered to be expressed only in 
lymphoid-cell lineages such as B, T, dendritic cells and macrophages [82]. According to 
microarray results, expression of IRF8 was IFNγ dependent and highly upregulated upon 
treatment with IFNγ and LPS (Tab 3-2). Treatment with LPS alone did not affect expression of 
IRF8. To support our genome-wide studies, we treated VSMCs isolated from WT, STAT1 and 
IRF8 deficient mice with IFNγ. We observed time dependent upregulation of IRF8 only in WT-
VSMCs. Expression of IRF8 was not present either in IRF8-/- or STAT1-/--VSMCs (Fig. 3-8 A). 
Next, we verified susceptibility of IRF8 to signal integration in cells from the vasculature. IRF8 







Fig. 3-8. IRF8 is expressed in the vasculature. A, VSMCs from WT STAT1-/-,and IRF8-/- were treated with 
IFNγ for indicated time points. RNA was isolated and subjected to PCR for IRF8 using βActin as internal 
control. B, Cell were treated as in Fig 3-1. qRT-PCR for IRF8, using GAPDH as internal control was 
performed in VSMCs (left panel) and HMECs (right panel). Data represent means of at least  
3 independent experiments ±SEM and p<0.05 was considered as significant. C, Representative Blot for 
IRF8. Protein extracts from treated cells were analyzed for IRF8 and GAPDH. Left panel presents data 
obtained from VSMCs and right from HMECs. 
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Only treatment with IFNγ led to the upregulation of IRF8 in WT-VSMCs and HMECs. Moreover, 
pretreatment of VSMCs and HMECs with IFNγ for 4h followed by LPS for another 4h resulted 
in amplification of IRF8 expression. IRF8 was not present in STAT1-/--VSMCs indicating STAT1 
dependent expression of IRF8. In analogy to the mRNA results, Western experiment confirmed 
upregulation of IRF8 upon treatment with IFNγ and amplification of its expression in the 
presence of both IFNγ and LPS in HMECs and WT-VSMCs but not STAT1-/ (Fig. 3-8 C).  
This result indicates STAT1 dependent expression of IRF8 upon stimulation with IFNγ and 
confirms amplification of IRF8 upon stimulation with IFNγ and LPS. 
 
IRF8 mediates IFNγ and LPS induced gene expression in vascular cells. 
IRF8 is an important transcription factor which regulates not only immune cells development 
but also their function and is associated with expression of several proinflammatory genes 
[82, 194]. Therefore, to further characterize the role of IRF8 in the vasculature, we evaluated 
expression patterns of Ccl5 and Nos2. Literature data indicates that expression of above 
mentioned genes in immune cells is IRF8-dependent [195].  
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Fig. 3-9. IRF8 participates in a crosstalk between IFNγ and LPS be regulating expression of Ccl5 and iNOS 
but not Cxcl10 and Cxcl9. VSMCs from WT and STAT1-/-, IRF8-/- were treated as described in Fig 1. RNA was 
isolated and qRT-PCR for Ccl5, iNOS (A) and Cxcl10, Cxcl9 (C) using Gapdh as internal control was 
performed. B, On the medium remained after treatment ELISA for Ccl5was performed. C, After treatment 
medium was refreshed and cells were cultivated for further 24h. 100µl was used to measure nitrite. Data 
represent means of at least 3 independent biological experiments ±SEM and p<0.05 was considered as 
significant. NS – not significant 
 
Expression patterns were evaluated by qPCR and compared with WT and STAT1-/- cells  
(Fig. 3-9). Indeed the IRF8 dependent regulation of Ccl5 and Nos2 on mRNA and on protein 
level (Fig. 3-9 A and B) was observed. Treatment with IFNγ and LPS led to amplification of Ccl5 
and Nos2 in WT and IRF8-/- VSMCs. However, response to both stimuli was highly attenuated 
in IRF8-/--VSMCs compared with WT-VSMCs. Nitrite accumulation (Fig. 3-9 C) and Ccl5 
expression (Fig. 3-9 B) measured in the medium confirmed that result. In contrast to Ccl5 and 
Nos2, expression of Cxcl10 and Cxcl9 in response to IFNγ and LPS in WT VSMCs was similar to 
that in IRF8-/--VSMCs (Fig. 3-9 D). 
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IRF8 is expressed in ECs and VSMCs from human carotid atherosclerotic plaques. 
To obtain further evidence for the expression of IRF8 in vascular cells in human tissue, we 
performed immunohistochemistry staining of IRF8 in human advanced atherosclerotic plaques 
of carotid arteries and compared to healthy vessels. While there was no positive IRF8 staining 
in control vessels (Fig. 3-10 A), human atherosclerotic lesions were positive for IRF8 and 





To specify which cells express IRF8, we performed fluorescent immunohistochemistry.  
We identified strong expression of IRF8 in CD68 positive cells (Fig. 3-11).    
Fig. 3-10. Expression of IRF8 in human atherosclerotic lesions. Staining of the sections prepared from normal human 
artery exhibited no presence of IRF8 (A, upper panel). In contrast, IRF8 could be detected in cells that correlate with 
expression for SMC marker in atherosclerotic plaque. Arrows represent examples of positive staining.  
 
Fig. 3-11. Fluorescent staining 
of in advanced carotid athero-
sclerotic plaques for IRF8. 
Abundance of IRF8 correlated 
with expression of macrophage 
marker (cells expressing CD68 
marker). Combined staining 
with FITC (macrophage) and 
Cy3 (IRF8) fluorescence dye 
were used. Cell nuclei were 
counterstained with DAPI.  
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In addition to macrophages (cells expressing CD68 marker), VSMCs seemed to be positive for 
this staining (Fig. 3-12 upper panel). However, the expression was very weak and not all cells 
were stained. Furthermore, ECs of intra-plaque neovessels were also positive for IRF8  
(Fig. 3-12 lower panel). In contrast, ECs covering the plaque showed negative staining (data 
not shown). Presented results indicate that IRF8 is expressed in human carotid plaques among 
inflammatory as well as non-inflammtory cells. However, these results are still not 




Fig. 3-12. Staining for IRF8 in human carotid plaques. Selected examples of fluorescent staining of 
VSMCs and ECs within neovessels in advanced carotid atherosclerotic plaques for IRF8. A combined 
staining with FITC (green, cells specific) and Cy3 (red, IRF8) fluorescence dye were used. Cell nuclei 




ECs and VSMCs sustain the blood flow and regulate the vascular tone, thus they play a pivotal 
role in maintaining homeostasis of the cardiovascular system. Nevertheless, in the presence of 
cardiovascular risk factors the cells that form the vessel wall are activated and demonstrate  
a phenotype that is characteristic of the host defense response. This change of the phenotype 
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results in the expression of proinflammatory genes such as cytokines and chemokines and  
is fundamental in the pathophysiology of many disorders, including atherosclerosis [196, 197]. 
  
In a previous chapter we showed that signal integration between important contributors  
of the inflammation is also present in non-immune cells. Our results suggested that in ECs and 
VSMCs, STAT1 creates a platform for crosstalk between IFNγ and TLR4 and thus triggers 
expression of proinflammatory genes such as Cxcl10. Here we present results which clearly 
confirm previous findings. Signal integration between both pathways led to high expression of 
Cxcl10 and iNOS, which was TLR4- and STAT1-dependent (Fig. 3-1). We carried out 
transcription profiling to further investigate how signal integration between IFNγ and TLR4 
modulates gene expression and, consequently, how this alteration affects vascular function. 
We identified 30 STAT1-dependent genes whose expression upon combined treatment was at 
least two-fold higher as compared to treatment with IFNγ and LPS alone. Functional analysis 
as presented in Table 3-3 revealed that these genes are involved in a number of biological 
processes related to inflammation, stress and wound healing. These included chemokines 
Cxcl9, Ccl12, Ccl8, Ccrl2, Cxcl10 and Ccl5, adhesion molecules (Cd40, Cd74), and the antiviral 
and antibacterial response genes Irf8, Rsad2, Mx1, Oasl, Gbp5, Nos2, Batf2 and Tnfrsf11a. 
Interestingly, meta-analysis performed in our laboratory identified the expression of a subset 
of genes in human plaques from the carotid and coronary artery [198]. Some of these genes, 
including CXCL9, CXCL10, CCL5, CCL8, CRCL2, CD74 and IRF8, have previously been implicated 
in atherosclerosis [89, 199]. However, other genes were not, such as GBP5, UBD, SECTM1, 
IFI16, UPP1 and FAM26F, and could therefore represent the potential novel biomarkers of 
atherosclerosis.  
 
Depending on the characteristic response pattern in WT-VSMCs, we could divide the genes 
listed in Table 3-2 into five groups (Fig. 3-2). Next we verified the expression pattern of 
synergistically amplified genes in STAT1-/--VSMCs. As was expected, a lack of STAT1 resulted in 
an abolished IFNγ response and in deprivation of signal integration upon combined treatment 
(Fig. 3-2 B). With regard to the LPS response, a lack of STAT1 resulted in ameliorated 
expression in 50% of the genes listed in Table 3-2. ELISA and qPCR, which was used to 
additionally determine the expression profile of selected genes, validated our microarray 
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results (Fig. 3-3). Promoter analysis confirmed the presence of a variety of cis-regulatory 
elements such as STAT-NFκB and IRF-NFκB modules, or combinations of separate ISRE-, STAT- 
or NFκB-binding sites. Most of the genes listed in Table 3-2 do not have a unique cis-
regulatory element, which strongly suggests the cooperative involvement of distinct 
transcription factors including NFκB, STAT1 and/or IRF in the transcriptional regulation of all of 
these genes in response to IFNγ and LPS. These results are in line with several studies that 
were performed in immune cells where the cooperative action of STAT1 and NFκB was related 
to gene expression in response to stimuli such as IFNγ and TNFα, IL-1β or LPS [132, 135-137, 
139, 143]. For example, it was recently reported that IFNγ and TNFα synergistically regulated 
the transcription of many inflammatory genes [135-137, 139] including CXCL9 [131], where 
independent interaction of STAT1 and NFκB was sufficient to mediate the transcriptional 
synergy [139]. Similar phenomena were observed for genes containing ISRE and NFκB 
elements. In this respect the NFκB motif in the GBP1 promoter was required for  
a transcriptional response to TNFα and IL-1β in cooperation with IRF1-binding ISRE [200]. 
A similar synergistic effect of TNFα with IFNγ and LPS with IFNγ was observed on the promoter 
activity of several other genes, such as ICAM-1 [201], NOS2 [202], CXCL10 or CCL5 [137, 203]. 
Our results strongly suggest that a mechanism of synergistic amplification, primarily described 
in immune cells and based on cooperation between NFκB and STAT1 or NFκB and IRF1, is also 
present in cells from the vasculature [185]. Because there were no specific cis-elements that 
could explain the differences in the expression patterns of these 30 genes, we suggest that  
the affinity of the different transcription factors and their interplay most likely determines the 
transcriptional response of a particular gene.  
 
A large group of genes listed in Table 3-2 belongs to the family of chemokines. This group of 
genes mediates chemotaxis of immune CD3+/CD45+ cells and, consequently, directs them 
towards the inflammation site. We performed migration assay (Fig. 3-4) to verify whether 
synergistic amplification of genes related to chemotaxis has a functional consequence. Indeed, 
we observed that increased migration of T-cells towards the medium remained after 
treatment of WT-VSMCs with IFNγ and LPS as compared to the conditioned medium from cells 
treated with each factor alone. In contrast, migration towards the medium remained after 
treatment of STAT1-/--VSMCs was attenuated. In addition, we confirmed amplification of Cxcl9 
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and Cxcl10 in ex vivo-treated aortas isolated from WT mice (Fig. 3-5). Furthermore, the 
literature data indicate the involvement of many chemokines, including CXCL9, CXCL10, CCL5, 
CCL8 and CCRL2, in leukocyte recruitment to the injured artery during vascular remodeling 
[193, 204, 205], and as such involvement in the pathogenesis of atherosclerosis. Therefore, to 
further confirm the results we performed IHC staining of atherosclerotic lesions isolated from 
human carotid arteries. In agreement with previously published data, we could confirm the 
presence of CXCL9 and CXCL10 in atherosclerotic lesions (Fig. 3-7). Importantly, we detected, 
for the first time, the presence of phosphorylated STAT1 which correlated with the expression 
of CXCL9 and CXCL10. These results, together with previously published data, point to the pro-
atherogenic role of STAT1 in cells from the vasculature in human vascular disease [79]. Most 
importantly, signal integration between IFNγ and LPS resulted not only in an increased 
abundance of chemokines but also contributed to vessel function by upregulation of Nos2. 
Inducible nitric oxide synthase has been found to promote vessel dysfunction and 
atherosclerosis [206]. Indeed, aortic rings isolated from WT treated by both stimuli had a 
highly ameliorated contractile response to norepinephrine and a dilator response to sodium 
nitroprusside (Fig. 3-6).  
 
IRF8 was also among the genes that were synergistically amplified upon treatment with IFNγ 
and LPS. This transcription factor was thought to be expressed only in immune cells. Our 
experiments clearly revealed its presence in VSMCs and HMECs at the mRNA as well as 
protein level (Fig. 3-8). However, expression of IRF8 was strictly regulated by IFNγ and was not 
present at the basal condition. These results suggest that IRF8 is involved in the regulation of 
gene expression downstream of STAT1. Promoter analysis identified the presence of the 
regulatory element that was recognized by both STAT1 and NFκB in the IRF8 promoter  
(Table 3-2), which thus suggests the importance of the cooperation of STAT1 and NFκB in the 
amplification of IRF8 expression. Consequently, IRF8 can be considered as an additional 
platform for the regulation of crosstalk between IFNγ and LPS in vascular cells. Interestingly, 
some evidence for IRF8’s role in this crosstalk exists in immune cells. Zhao et al. showed that 
the synergistic induction of pro-inflammatory genes, such as IL1, IL6, IL12 and TNFα, is IRF8-
dependent in macrophages [115]. Moreover, recent data pointed to the role of IRF8 in TLR4-
mediated NFκB activation [207]. Indeed, our experiments performed in ECs and VSMCs 
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identified Ccl5 and iNOS (but not Cxcl9 and Cxcl10) as potential IRF8 targets (Fig. 3-9).  
These data are in line with results obtained in macrophages where cooperation of IRF8 with 
IRF1 and NFκB was essential for the IFNγ and LPS response. While interaction of IRF8 with IRF1 
facilitated the response to IFNγ, the response to LPS was mediated by interaction between 
IRF8 and NFκB at the promoter site [115, 144, 208]. We hypothesize that a similar mechanism 
of interaction between IRF8 and other transcription factors regulates the expression of genes 
involved in inflammation, such as Ccl5 and Nos2, which play a crucial role in atherogenic 
processes [209]. Indeed, in silico promoter analysis predicted the presence of an IRF-NFκB 
module in Ccl5 and Nos2 promoters. On the other hand, the promoters of both genes also 
contain a potential STAT1-NFκB module, which suggests the additional involvement of STAT1 
as well.  
 
Finally, we performed IHC staining of the material isolated from arteries affected with 
atherosclerosis to study whether IRF8 is expressed in the vessel wall. While expression of IRF8 
was not detected in the control material, IRF8 expression could be detected in infiltrating 
macrophages and in VSMCs and ECs in the atherosclerotic plaque (Figs. 3-10-12). However, 
the expression in vascular cells seemed weaker and not all of these cells were positive for 
IRF8; thus further research will be required to prove the expression of IRF8 in atherosclerotic 
lesions. Nevertheless, our IHC results correlate with the fact that IRF8 expression is not 
detected in vascular cells but is completely dependent on pro-atherogenic stimuli, such as 
IFNγ and LPS, whereas a constitutive IRF8 expression pattern is present in immune cells [82].  
 
In conclusion, our results indicate that in ECs and VSMCs, STAT1 and IRF8 together with the 
cooperation of other transcription factors such as IRF1 and NFκB orchestrate a platform for 
crosstalk between IFNγ and TLR4. Consequently, STAT1- and IRF8-mediated signal integration 
leads to synergistic amplification of genes involved in several proinflammatory processes such 
as chemotaxis, migration and oxidative stress. Because these processes are involved in the 
development and progression of atherosclerosis, STAT1 and IRF8 together with their 
downstream genes could represent potential targets of therapeutic intervention.  
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Chapter 4  
Signal Transducer and Activator of Transcription protein (STAT)-1 in 




Hypertension is one of the major risk factors for cardiovascular mortality and morbidity [210].  
In Poland, prevalence of hypertension was reported in 32% of the adult population [211]. 
Among them only one third was aware of the disease and etiology of the disease remained 
unknown in 95% of the cases [211]. Angiotensin (Ang) II, a crucial mediator of the renin-
angiotensin system, not only regulates the vascular tone but also induces inflammation and 
contributes to end organ damage. Ang II-induced hypertension causes cardiac remodeling 
characterized by inflammation, fibrosis and hypertrophy [212]. Genetically modified mice with 
kidney specific elevation of Ang II, have elevated inflammation and kidney fibrosis [213]. 
Although the exact mechanism of immune system sensitization remains unknown, it has been 
observed that Ang II stimulates the expression of chemokines (Ccl2, Cxcl10), cytokines (Il6 or 
TNFα), and adhesion molecules (VCAM) [214-217]. Ang II can also act on monocyte 
differentiation and T cell function [31]. Treatment with angiotensin-converting enzyme (ACE) 
inhibitors and Ang II receptor blockers not only lowers the blood pressure but also diminishes 
the expression of adhesion molecules and decreases the number of adhered leukocytes [218-
220]. Recent studies indicate that at least partially the function of Ang II is mediated through 
the activation of lymphocytes and subsequent IFNγ secretion [73, 74, 221]. IFNγ or IFNγ 
receptor-deficient mice revealed not only improved vessel but also cardiac function, reduced 
inflammation and heart fibrosis despite Ang II infusion. The action of IFNγ is mediated through 
the JAK/STAT pathway [118]. Stimulation with IFNγ triggers conformational changes of the 
receptor and facilitates phosphorylation of the JAK1 and JAK2 kinases, which consequently 
phosphorylates transcription factor STAT1. This canonical mediator of IFNγ signaling forms 
active dimers that trigger expression of STAT1-dependent genes such as Cxcl10 and Ccl2 [161, 
222]. Importantly, not only IFNγ but also Ang II can reveal its actions via activation of 
important components of the JAK/STAT pathway [223]. Ang II cooperates with the JAK2 kinase 
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to induce vessel contraction, and inhibition of JAK2 phosphorylation blocks blood pressure 
elevation [224, 225]. Similarly to IFNγ, also Ang II contributes to activation of the JAK/STAT 
pathway, thus leading to the expression of nicotinamide adenine dinucleotide oxidase 
(NADPH) and, as a consequence, upregulation of ROS production [226, 227]. Mechanical 
stretch activates JAK/STAT via autocrine/paracrine-secreted Ang II [228].  
 
Despite providing evidence for the importance of the JAK/STAT pathway in the regulation of 
Ang II response, surprisingly little is known about the role of transcription factor STAT1- and 
STAT1-dependent genes in such pathological settings. Although it has been shown that 
activated Ang II receptor I (AT1R) associates with the JAK2 kinase and triggers STAT1 
phosphorylation, potential consequences of STAT1 activation are not fully understood [229, 
230]. Both Ang II and STAT1 were identified to regulate autophagy, a catabolic process that 
degrades cytoplasmic components within the lysosome and is related to fibrosis and 
hypertrophy [231, 232].  
Thus, to investigate the role of STAT1 in hypertension and hypertensive end-organ damage,  
we applied an Ang II-induced model of hypertension in STAT1-deficient mice. We 
hypothesized that activation of STAT1 during Ang II infusion upregulates chemokines, 





Mice wild-type C57BL/6 (WT) were obtained from Charles River Laboratories. STAT1-/- 
knockouts mice on C57BL/6 background were kindly provided by Thomas Decker All strains 
were housed under controlled conditions of temperature (21°C) and were maintained on 
normal mouse chow diet and water ad libitum. All experiments performed in accordance with 
institutional guidelines. Angiotensin II (Sigma) in a concentration 1,5µg/g/day was infused 
using mini-osmotic pump (Alzet, model 2004) which was implanted subcutaneously under 
inhaled isoflurane anesthesia and buprenorphin. Blood pressure was measured using tail cuff 
pletysmography.  
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Wire myograph and contractility studies 
To measure circulatory function, descending thoracic aorta were cut into 2mm long rings and 
mounted in a 4-channel wire myograph (620M, Danish Myo Technology, Aarhus, Denmark) in 
the organ chamber filled with physiological saline solution (PSS) containing 118,99mM NaCl, 
4,69mM KCl, 1,17mM MgSO4*7H2O, 1,18mM KH2PO4, 2,5mM CaCl2*2H2O, 25mM NaHCO3, 







During the experiment PSS buffer was aerated with carbogen (95% O2+ 5%CO2). After 20min 
of incubation (at 37°C), calibration of the force transducer was performed [190]. 
Subsequently, vessels were pre-streched to obtain optimal passive tension. Next, vascular 
functions were analyzed. Contractility was evaluated by substitution of PSS buffer for high 
potassium physiological saline solution (KPSS; 74,7mM NaCl, 60mM KCl, 1,17mM 
MgSO4*7H2O, 1,18mM KH2PO4, 1,6mM CaCl2, 14,9mM NaHCO3, 0,026mM EDTA, 5,5mM 
Glucose). For testing viability, vessels were subjected to norepinephrine-induced constriction 
followed by acetylcholine dilation (Fig. 4-1 B). Activation of α-adrenergic receptors by 
noradrenaline triggers the release of Ca+2 from the sarcoplasmic reticulum followed  
by membrane depolarization by activated chloride channels. This results in augmented 
Fig. 4-1. Protocol for the myograph experiment. A, The wire myograph 620M (left picture) and the chamber 
with mounted aortic ring (right picture). B, On the isolated aortic rings, viability test with 10-5 mol/L of 
noradrenaline (NE) followed by 10-5 mol/L of acetylcholine was perfomed. C, Noradrenaline was used in 
stepwise increased, cumulative concentration ranging from 10-11 to 10-6 mol/L (N1-N9) and followed by 
acetylcholine dose-response curve from 10-10 to 10-5 mol/L (A1 to A11). D, Calcium-induced (receptor 
independetn) vasoconstriction dose-response curve was perfomed. The myograph gives output readings as 
absolute tension generated elicited by vasoconstriction/vasodilatation in millinewton (mN). 
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extracellular Ca+2 influx in the plasma membrane of the VSMCs and leads to an increase in 
intracellular Ca+2 concentration and vasoconstriction [233]. Opposite to norepinephrine, 
acetylcholine triggers endothelium-dependent vasodilatation via stimulation of muscarinic 
receptors. Acetylcholine leads to the release of nitric oxide from endothelium and causes 
opening of the potassium channels in the VSMCs thereby leading to hyperpolarization [234]. 
Action of acetylcholine is endothelium mediated and thus only vessels with intact 
endothelium fully respond to acetylcholine-mediated dilation. After washing out with PSS 
buffer and resting for 15 minutes, norepinephrine and acetylcholine dose-response curves 
were performed (Fig. 4-1 C). Noradrenaline was used in stepwise increased, cumulative 
concentration ranging from 10-11 to 10-6 mol/L (N1-N9), followed by acetylcholine dose-
response curve from 10-10 to 10-5 mol/L (A1 to A11). Subsequently, vessels were washed with 
PSS buffer and left resting for 20 minutes. Finally, cells were washed with PSS buffer and 
calcium sensitivity was assessed by stepwise increases of calcium concentration (0 - 3mmol/L) 
in the organ bath under depolarizing conditions (125mmol/L potassium) starting at 0mmol/L 
calcium in the bath solution (Fig. 4-1 D).  
 
RNA analysis 
Total RNA from kidney and heart was isolated using RNAeasy Mini Kit (Qiagen). 10-20mg of 
the tissue was lysed using TissueLyser (Qiagen, 2x30Hz, 2min) in RLT buffer. Next, samples 
were homogenized using QIAshredder columns and RNA isolation was perfomed according to 
the manufacture’s protocols. Isolated aortas were cleaned from perivascular fat and snap 
frozen on liquid nitrogen. Aorta was ground up with pestle and 1ml of Trizol was added. Total 
RNA from aorta was isolated using Trizol method followed by PureLink RNA kit (Life 
Technologies). cDNA was prepared using iScript cDNA synthesis kit (Bio-rad) following the 
manufacture’s protocols. Quantitative real-time PCR was performed by using a MyiQ Real 
Time PCR detection system provided by Bio-rad. Forward and reverse primers are depicted in 
Table 4-1. The 2-ddCt method was applied for quantification [155]. Fold change in the target 
gene were normalized to GAPDH and relative to the mean expression at untreated sample. 
The results are expressed as fold of control from at least 3 independent assays. 
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Table 4-1. List of primers used in chapter 4 
Gene Name Forward Reverse 
Gapdh TCGGTGTGAACGGATTTGGC TTTGGCTCCACCCTTCAAGTG 
MCP1 (CCL2) GCTGTAGTTTTTGTCACCAAG GATTTACGGGTCAACTTCACA 
Nox4 ACAGAAGGTCCCTAGCAGGAG CAACAAACCACCTGAAACATGC 
Cxcl10 TCATCCCTGCGAGCCTATCC GGAGCCCTTTTAGACCTTTTT 
Cxcl9 CTGCCATGAAGTCCGCTGTTCT TCCCCCTCTTTTGCTTTTTCTT 
Col type 3A1 
 
CCTCAGACTTCTTTCCAGCCG GTCTTGCTCCATTCCCCAGTG 
iNOS (NOS2) TGGGGCAGTGGAGAGATTTT TCTGGTCAAACTCTTGGGGT 
p47phox AGAAGGCTGGGGAGGAGATA TTCCGTTTGGTGCTCTCTGTG 
p22phox GCCCTCCACTTCCTGTTGTC CCTCCTCTTCACCCTCACTC 





Western blot analysis 
10-20mg of tissue was lysed using TissueLyser (Qiagen, 2x30Hz, 2min) in RIPA (Sigma) 
containing protease and phosphatase inhibitors (Roche). Protein concentrations were 
measured using BCA protein assay (Pierce). Protein extracts were heated with sample buffer 
(Life Technologies) containing dithiothreitol (90˚C, 10min) and loaded on NuPAGE 4-12% Bis 
Tris Gel (Life Technologies). After electrophoresis (200V, 45min), proteins were transferred 
onto PVDV filter using wet transfer system (Bio-rad, 30V, 90mA, 16h at 4˚C). Membranes were 
blocked with 5% BSA in TBS-Tween (TBST) and incubated with primary antibodies: rabbit 
monoclonal to LC3A/B antibody (overnight, 1:1000, Cell Signaling, 12741), or GAPDH 
(overnight, 1:15000, Cell Signaling, 5174). After washing in TBST for 30min at RT, membranes 
were incubated with secondary goat anti-rabbit antibody (1:15000, 30min at RT, Santa Cruz 
Biotechnology sc-2004). Next, membranes were washed in TBS for 30min and visualized using 
Luminata Forte or Luminata Classico (for GAPDH) Western HRP substrate (Millipore) in INTAS 
imaging system (Intas, Germany). 
 
Hydroxyproline measurement assay 
Hydroxyproline was measured using Hydroxyproline assay provided by QuickZyme 
Biosciences. Briefly, approx. 20mg of the tissue were hydrolyzed in 6M HCl (Sigma) and 
incubated for 20h at 95°C together with provided standard. Samples were cooled to the RT, 
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centrifuged and transferred into new tube. Supernatants were diluted in 4M HCl and mixed 
with 75ul of the assay buffer and incubated 20min at RT. Next, 75ul of the detection reagent 
was added and incubated for 60min at 60°C in an oven. After incubation absorbance at 570nm 
was measured. Data were analyzed using MARS data analysis software (BMG Labtech). 
 
Immunohistochemical analysis 
Part of the isolated tissue were fixed in 10% buffered formalin and embedded in paraffin. 
Sections (4 µm thick) were cut and stained for collagen via Picosirius red. For characterisation 
of the cells within isolated tissues, sections were treated with antibody for all nucleated 
hematopoietic cells (rat anti mouse CD45 BD Pharmingen 550539) dilution 1:50 overnight at 
RT. Following incubation with primary antibody visualisation was performed by 
peroxidase/DAB ChemMate Detection Kit according to the manufacturer’s instructions. 
 
Promoter Analysis  
Promoters for amplified STAT1 dependent genes were screened using GENOMATIX software 
(http://www.genomatix.de/). [160] The promoter regions from -1000 to +100bp were 
searched for binding sites (V$IRF1.01 V$ISGF3G.01 V$ISRE.01 V$ISRE.02 V$CREL.01 
V$NFKAPPAB.01 V$NFKAPPAB.02 V$NFKAPPAB65.01 V$STAT.01 V$STAT1.01 V$STAT1.02)  
or models with core similarity at least 0.85 (V$STAT3.02 V$STAT3.01). 
 
Statistical Analysis  
Data are presented as mean ± SEM. For comparisons between more than two groups one-way 
ANOVA with Tukey post-hoc test was used. In all other experiments comparing two groups, 
Student’s t-test was used. In contractility studies, for comparison of maximum constriction 
among groups two-way ANOVA test with Bonferroni post hoc test was used. A probability 





70 | P a g e  
 
Ang II-induced and STAT1 mediated cardiac damage 
To characterize the role of STAT1 in hypertension and hypertensive induced end organ 
damage we subcutaneously infused Ang II in WT and STAT1-/- mice. Basal systolic blood 
pressure (BP) was the same among all groups and Ang II increased systolic BP in the same 
manner in WT and STAT1-/- (Fig. 4-2 A). Likewise, there was no difference in basal heart weight 
to body weight (HW/BW) ratio and both groups presented the same rate of cardiac 




Fig. 4-2. Role of STAT1 in hypertension and hypertensive induced end-organ damage. C57BL/6 (WT) and 
STAT1-/- mice (C57BL/6 background) were treated for 28d with 1,5µg/g/day angiotensin II (Ang II), which was 
administered subcutaneously via osmotic minipump. A, Noninvasive blood pressure measurements obtained 
via the tail cuff method (n≥6 per group) B, Heart weight to body weight ratio (HW/BW) measured in Ang II 
treated STAT1 knockout vs WT mice. 
 
Next, we investigated the role of STAT1 in Ang II-induced inflammation of the heart.  
Staining for CD45+ cells disclosed significantly increased infiltration of inflammatory cells in WT 
hearts which was markedly reduced in STAT1-/- mice upon chronic infusion of Ang II (Fig. 4-3). 
Sirius red staining demonstrated less perivascular fibrosis in STAT1-/- compared to WT treated 
with Ang II (Fig. 4-4 A). This result correlated with ameliorated expression of collagen in 
knockout mice (Fig. 4-4 B) and reduced tissue content of hydroxyproline in STAT1-/- exposed to 
Ang II (Fig. 4-4 C). Because STAT1 play an important role in the regulation of chemokine 
expression, we studied expression of these genes in heart tissue. Indeed, we observed 
increased expression of Ccl2 (Mcp-1), Cxcl9, Cxcl10 chemokines and marker of nitric oxide iNos 
only in hearts of stimulated WT animals (Fig. 4-5). Expression of inflammatory mediators 
correlated with the immune cell infiltration.  
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Fig. 4-3. Inflammatory cell infiltration in heart of animals exposed to Ang II. A, Representative images of 
CD45 immunohistochemical staining of heart tissue. B, The column graph represents the number of 
positive cells per tissue slide examined (data are presented as mean ± SEM, n≥4 mice/group). 
 
 
Fig. 4-4. STAT1 deficiency reduces heart fibrosis. A, Representative images of Sirius red staining of the 
heart tissue. B, RNA from heart was isolated and subjected to qRT-PCR for collagen (col3a1) using GAPDH 
as internal control. B, additionally, to evaluate cardiac collagen content, tissue hydroxyproline assay was 
perfomed (C). Data for n≥4 per group ±SEM. 




Fig. 4-5. STAT1 deficiency reduced expression of proinflammatory mediators in animals 
exposed to Ang II. RNA from heart was isolated and subjected to qRT-PCR for Cxcl10, 
MCP-1 (CCL2), Cxcl9 and iNOS using GAPDH as internal control n≥4 per group ±SEM.  








Fig. 4-6. Macrovascular function in WT and STAT1-deficient mice exposed to Ang II vs. 
control. WT and STAT1-/- mice were treated for 14d with 1,5µg/g/day Ang II, administered 
subcutaneously via osmotic minipump. Isolated aortic rings were tested for. response to 
norepinephrine and acetylcholine using the wire myograph. Noradrenaline was used in 
stepwise increased, cumulative concentration ranging from 10-11 to 10-6 mol/L and followed 
by acetylcholine dose-response curve from 10-10 to 10-5 mol/L A, Reaction to noradrenaline 
and acetylcholine in WT. ***p0.001< vs. WT control; *p<0.001 vs. WT control; •••p0.001< 
vs. WT control; ••p0.01< vs. WT control. B, Reaction to noradrenaline and acetylcholine in 
aortic rings isolated from STAT1-/-. ***p0.001< vs. STAT1-/- control; *p0.05< vs. STAT1-/- 
control; NS not significant. Aortas isolated from at least 3 animals per group were taken 
±SEM. Two-way ANOVA test with Bonferroni post hoc test was used. 
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Stat1-mediated effects of Ang II-infusion on vessel wall 
One key factor for Ang II-induced hypertension is the macrocirculatory function.  
Using myograph device, the noradrenaline dependent vasoconstriction and acetylcholine 
dependent relaxation was assessed. Aortic rings from WT mice exposed to Ang II had 
increased vasoconstriction responses to noradrenaline, presented as a percentage of maximal 
constriction to KPSS. (Fig. 4-6 A left panel) (Control WT: 75% vs. Ang II WT: 135%). In line with 
these results we observed that chronic Ang II infusion impaired endothelium-dependent 
vasodilatation (Fig. 4-6 A right panel) (control WT: 81.7% vs. Ang II WT: 39.2%). Aortic rings 
from STAT1-/- mice exposed to Ang II had increased vasoconstriction responses  
to noradrenaline, (Fig. 4-6 B left panel) (control STAT: 80.8% vs. Ang II STAT1-/-: 128.9%). 
Interestingly, STAT1 animals infused with Ang II did not reveal impaired endothelium-






In the next step we compared aortic function of WT and STAT1-/- animals exposed to Ang II. 
STAT1−/− and WT groups had a similar maximum vasoconstriction after chronic angiotensin 
infusion (Fig. 4-7 A). Most importantly, only WT tend to have ameliorated acetylcholine 
Fig. 4-7. STAT1 protects against endothelial dysfunction. Macrovascular function in WT mice 
exposed to Ang II vs STAT1
-/-
 was analyzed via wire myograph. Noradrenaline was used in 




mol/L (A) and followed 




mol/L (B). **p<0.01, NS not significant. 
Data for n≥3 per group ±SEM. Two-way ANOVA test with Bonferroni post hoc test was used. 
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dependent vasodilation in aortas which indicates that STAT1-/- are protected from Ang II 
infused vascular dysfunction (Fig. 4-7 B). 
 
 
Fig. 4-8. STAT1 deficiency reduces expression of ROS marker in animals exposed to Ang II. 
RNA from aorta was isolated and subjected to qRT-PCR for Ccl2 (MCP-1), Nox4, p47phox, 
p22phox  using GAPDH as internal control n≥4 per group ±SEM. 
 
Similarly as in the case of the heart, increased expression of inflammatory marker was 
detected in the aortic tissue of WT but not STAT1-/-. WT infused with Ang II revealed increased 
abundance of Mcp-1 (Ccl2) as compared to the control (Fig. 4- 8, upper left panel). To identify 
the potential cause of the abolished acetylcholine-mediated vessel relaxation, we verified 
presence of oxidative burst. ROS are known to be upregulated during Ang II stimulation and 
are associated with endothelial dysfunction. Indeed, we observed increased expression of 
oxidative stress markers p22phox, p47phox and Nox4 only in aortas of WT but not STAT1-/- 
exposed to Ang II (Fig. 4-8). Promoter analysis of p22phox, p47phox and Nox4 revealed 
presence of binding sites characteristic for STAT1, STAT3 but also for IRF1, NFκB and ISGF3γ 
complex, providing additional evidence for the direct role of STAT1 in regulating NADPH 
oxidase expression (Fig. 4-9).  
 
 





Fig. 4-9. Promoter analysis of Nox4, p47phox, p22phox. The promoter regions from -1000 to +100bp 
were searched for binding sites using a prediction algorithm (MatInspector, GENOMATIX software, 
http://www.genomatix.de/ [160]). To locate binding sites for STAT1, STAT3 IRF1 predefined matrices 
were used (V$IRF1.01 V$ISGF3G.01 V$ISRE.01 V$ISRE.02V$CREL.01 V$NFKAPPAB.01 V$NFKAPPAB.02 
V$NFKAPPAB65.01 V$STAT.01 V$STAT1.01 V$STAT1.02, V$STAT3.02 V$STAT3.01) Only sites with core 
similarity above 0.85 were selected. Start indicates position of ATG codon. In brackets matrix similarity 
score is given (the higher the number, the more conserved sequence is present). 
 
 
Stat1-mediated effects of Ang II-infusion on kidney. 
Next, we evaluated role of STAT1 in Ang II mediated renal damage. Alike in heart we could 
observe upregulation of inflammatory mediators Cxcl9, Ccl2 as well as fibrotic (col3a1)  
and nitric oxide marker (Nos2) in WT but not STAT1-/- mice upon chronic infusion of Ang II  
(Fig. 4-11). This was accompanied by reduced infiltration of CD45+ cells STAT1-/- animals  
(Fig. 4-10). 
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Fig. 4-10. Inflammatory cell infiltration in kidney of animals exposed to Ang II.  
A, Representative images of CD45 immunohistochemical staining of kidney tissue. B,  
The column graph represents the number of positive cells per tissue slide examined (data are 
presented as mean ± SEM, n≥4 mice/group).  
 
 
Fig. 4-11. Reduced expression of proinflammatory mediators in kidneys of STAT1-deficient 
animals exposed to Ang II. RNA from kidney was isolated and subjected to qRT-PCR for Cxcl9, 
MCP-1 (Ccl2), col3a1 and iNOS using GAPDH as internal control n≥4 per group ±SEM. 
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Interestingly, despite of decreased inflammatory cells infiltration, STAT1-/- exposed to Ang II 
revealed markedly higher expression of Neutrophil gelatinase-associated lipocalin (NGAL)  
as well as massive increase in albuminuria, indicating increased tubular and glomerular 
damage in the absence of STAT1 (Fig. 4-12). 
 
 
Fig. 4-12. STAT1 deficiency disturb kidney function. A, RNA from kidney was isolated and 
subjected to qRT-PCR for NGAL using GAPDH as internal control. B, Urine was collected in 
metabolic cage for 24h. Albumin and creatinine was measured using commercially available 
ELISA. n≥4 per group ±SEM. 
 
 
Fig. 4-13. STAT1 participates in autophagy. Protein extracts from kidneys of 3 animals 
exposed to Ang II and their controls (3) were analysed by Western blot for LC3. 
 
We hypothesized disturbed autophagy to be a cause of ameliorated kidney damage. Thus, we 
verified expression of one of the most important marker of autophagy, LC3-II protein which is 
created by cleavage of soluble LC3-I [236]. While expression of LC3-II did not change in WT 
animals treated with Ang II, expression of LC3-II was increased in STAT1-deficient mice 
exposed to Ang II (Fig. 4-13). These results indicate that STAT1 not only activates expression of 
proinflammatory genes that are important for immune cell infiltration but also may disturb 
processes related to autophagy and thus influence organ damage.  




Although the mechanism is not fully understood, several studies indicate that Ang II not only 
upregulates blood pressure but also affects the immune response by amplifying genes related 
to inflammation. The results presented in this chapter indicate that STAT1 may participate in 
an Ang II-mediated inflammatory response. We have shown that chronic Ang II infusion 
causes similar increases in systolic BP and heart hypertrophy in WT- and STAT1-deficient mice. 
However, STAT1-/- animals with Ang II-induced hypertension exhibited highly ameliorated 
expression of proinflammatory mediators (Cxcl9, Cxcl10, Ccl2, iNOS) in the heart and kidney, 
which was correlated with reduced CD45+ cell infiltration, decreased production of 
extracellular matrix components and, consequently, reduced organ injury. Recent evidence 
pointed to the importance of the JAK/STAT pathway in Ang II-mediated hypertension and 
hypertensive end-organ damage. Expression of IFNγ was upregulated in an Ang II-induced 
model of hypertension [31], and IFNγ-deficient mice had reduced heart infiltration by 
macrophages, which was associated with decreased fibrosis [73, 74].  
Furthermore, these experiments indicated that, at least partially, the function of Ang II is 
mediated through the activation of lymphocytes and subsequent IFNγ secretion [73, 74, 221]. 
Importantly, recent studies pointed to the fact that also Ang II can reveal its actions via 
activation of important components of the JAK/STAT pathway [223]. Ang II cooperates with 
the JAK2 kinase to induce vessel contraction, and inhibition of JAK2 phosphorylation blocks 
blood pressure elevation [224, 225]. Our results demonstrate that the mechanism of Ang II 
blood pressure regulation is STAT1-independent. STAT1 infused with Ang II had similar 
increases in systolic BP and heart hypertrophy as WT animals (Fig. 4-2). However, STAT1 
animals exposed to Ang II revealed reduced expression of inflammatory markers and reduced 
inflammatory cell infiltration (Figs. 4-3-4-5). Several studies have indicated the contribution of 
inflammation to the progression of fibrosis, which is defined by the accumulation of an 
extracellular matrix component (e.g. collagen, fibronectin) and gradual loss of organ function 
[237, 238]. During chronic Ang II infusion, resident and infiltrating leukocytes promote injury 
by production of proinflammatory cytokines and ROS as well as activating myofibroblasts that 
express extracellular matrix components. Thus, expression of chemokines is one of the initial 
steps of organ damage and preventing their recruitment may ameliorate tissue injury. Indeed, 
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literature data support this theory. Mice lacking the receptor for Ccl2 (Mcp1) infused with Ang 
II had ameliorated vascular inflammation and remodeling accompanied by reduced ROS 
production and fibrosis as compared to the CCR2+/+ animals [239, 240]. Expression of Mcp1 
correlated with macrophage infiltration and albuminuria in patients with chronic kidney 
disease [241]. Elevated levels of chemokines were observed in patients with hypertension 
[211]. Increased levels of Cxcl10 and Ccl2 were found in patients with essential hypertension, 
and treatment with angiotensin-converting-enzyme inhibitor lowered their expression [242, 
243]. Our data indicate that STAT1 plays a crucial role in regulating chemokine expression in 
response to Ang II stimulation. Mice lacking STAT1 had reduced expression of Ccl2 and Cxcl10 
but also Cxcl9 as compared to WT infused with Ang II (Fig. 4-5). These results, together with 
reduced production of ROS, may explain ameliorated fibrosis in STAT1-/- animals.  
 
To answer the question whether inflammatory activity of STAT1 is directly mediated through 
the action of Ang II, we performed in vitro stimulation of vascular cells with Ang II (data not 
shown). Although we were able to observe temporal STAT1 tyrosine phosphorylation,  
we could not detect any of the proinflammatory markers that were observed in our in vivo 
model. This suggests that action of Ang II on the activity of STAT1 is indirect and very likely 
IFNγ-dependent. Other potential activators of STAT1 may be related to the TLR4 and NFκB 
pathway [244, 245]. Spontaneously hypertensive rats demonstrated enhanced expression of 
the TLR4 receptor in cardiac tissue and the central blockade of TLR4, improved cardiac 
function and attenuated myocardial inflammation [101, 246]. Moreover, NFκB suppression 
markedly attenuated Ang II-induced organ injury [247]. It is very likely that functional 
cooperation between NFκB and STAT1 also appears in such a model of inflammation and is 
essential for efficient expression of many chemokines, such as Cxcl9, Cxcl10, or Ccl2.  
 
We found increased production of chemokines in the vasculature which was accompanied by 
increased expression of oxidative stress markers in WT but not STAT1-/- exposed to Ang II (Fig. 
4-8). Accelerated production of ROS by NADPH oxidases initiates endothelial dysfunction,  
a hallmark of the onset and progression of vascular disease [248]. There are seven members 
of the family, of which Nox1, Nox2, Nox4 and Nox5 enzymes are expressed in cardiovascular 
tissues. These enzymes, together with their regulatory subunits, e.g. p22phox or p47phox, 
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in pathological conditions contribute to progression of the disease, including hypertension 
[249]. Interestingly, there is cooperation between the JAK/STAT1 pathway and NADPH 
oxidases. Some studies have indicated that activation of the JAK/STAT pathway by Ang II 
depends on the Nox-derived ROS [227]. Recently, expression of this regulatory component of 
NADPH oxidase was hypothesized to be STAT3, but also STAT1-dependent [226]. Our in silico 
promoter analysis (Fig. 4-9) confirmed the observation indicating that action of STAT1 is not 
only limited to the regulation of chemokine expression but may also affect expression of 
NADPH oxidases in the vessel wall. In addition to the STAT3-binding sequence, we could 
identify the presence of a characteristic sequence for the STAT1, IRF1, NFκB and ISGF3γ 
complex, thus indicating possible functional cooperation of these transcription factors in 
regulating NADPH oxidase expression.  
 
Increased production of ROS by NADPH oxidases causes reduced nitric oxide (NO) 
bioavailability leading to ameliorated vessel relaxation [250] (Fig.4-6, 4-7). Dilation of the 
vessel is mediated mainly through the conversion of L-arginine to L-citrulline and nitric oxide 
synthesis by NO synthase with the involvement of many cofactors, including NADPH, FMN, 
FAD, calmodulin, heme, and tetrahydrobiopterin (BH4). However, in the presence of ROS, NO 
synthase is “uncoupled”. At that stage the enzyme is not able to convert amino acids but is 
still able to transfer electrons from NADPH to molecular oxygen and to form superoxide (Oˉ2) 
[251]. This process reduces the amount of available NO and promotes endothelial 
dysfunction. Due to lower NO bioavailability, vessels are not able to fully dilate in response to 
the release of endothelial-mediated vasodilators such as acetylcholine. Thus, increased 
expression of ROS has an effect on macro- and microcirculatory function. Treatment with Ang 
II led to increased maximal response and the left shift in noradrenaline sensitivity in WT 
animals. Furthermore, there was a highly reduced response of endothelial cells to 
acetylcholine. Compared to WT, STAT1 animals treated with Ang II had similar maximal 
constriction. As there was no difference in systolic BP, this result was expected. However, in 
contrast to WT, STAT-/- exhibited preserved endothelium function manifested by unaffected 
response to acetylcholine. Ameliorated ROS production together with decreased expression of 
proinflammatory mediators may explain the protective phenotype of STAT1-/- animals in the 
vasculature. 
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Similarly as with the heart and vasculature, abolished expression of inflammatory genes and 
markers of fibrosis in the kidneys of STAT1-deficient animals was detected (Figs. 4-10, 4-11). 
Nonetheless, we observed increased expression of NGAL, a marker of tubulointerstitial 
damage, and highly increased albuminuria indicating enhanced Ang II–induced glomerular 
damage in STAT1-deficient mice (Fig. 4-12). The mechanism which explains this phenomenon 
may be related to autophagy [252]. Autophagy is a prosurvival, highly regulated catabolic 
process responsible for the degradation of cytoplasmic components. It is based on the 
formation of double membrane vesicles containing damaged proteins or organelles which 
fuse with the lysosome, thus leading to digestion of their content. This process is essential for 
cells exposed to stress factors such as hypoxia, infection, or oxidative stress, and alteration of 
autophagy may be a source of a pathological state [253, 254]. Autophagy can also regulate 
inflammation and fibrosis [255, 256]. Zhao et al. showed that an autophagy-deficient mouse 
exposed to Ang II had an increased level of reactive oxygen species (ROS) production as well 
as increased levels of inflammation and cardiac injury. Ang II was found to promote autophagy 
in podocytes and its abrogation triggered glomerulopathy and proteinuria [257, 258]. 
 
Our results indicate that a lack of STAT1 disturbed autophagy in the kidney (Fig. 4-13). STAT1 
animals exposed to Ang II had higher levels of LC3-II as compared to WT animals. These results 
are in line with studies performed by Marko et al. [74]. IFNγ receptor knockout mice infused 
with Ang II had highly elevated levels of albuminuria accompanied by a decreased number of 
podocytes and an increased amount of LC3 in the glomeruli. LC3 is crucial for vesicle 
(autophagosome) formation and maturation [236]. After synthesis, proLC3 is processed to 
LC3-I and conjugated with phosphatidylethanolamine to form LC3-II. Increased levels of LC3-II 
may indicate either enhanced autophagosome synthesis (increased autophagy) or reduced 
vesicle turnover (decreased autophagy). In order to interpret observable changes in the LC3 
amount, further experiments including transmission electron microscopy (TEM) as well as 
stimulation with compounds inhibiting autophagosome degradation are needed [259].  
 






Moreover, it is still unclear how STAT1 affects autophagy, and studies that have been 
performed until now are partially contradictory. Increased activation of STAT1 caused by 
histone deacetylase 4 was associated with ameliorated autophagy, accelerated inflammation 
and podocyte injury in the model of diabetic nephropathy [260]. McCormick et al. showed 
that STAT1-/- mice undergoing ischemia-reperfusion (I/R) injury had smaller infarcts and 
enhanced levels of autophagy. Inhibition of autophagy abrogated cardioprotection observed 
in STAT1-/- animals following I/R injury [232]. These results indicate that STAT is involved in the 
inhibition of autophagy. STAT1 was also found to co-immunoprecipitate with LC3, and hearts 
from STAT1-/- subjected to ex vivo I/R had an increased number of damaged mitochondria 
located within double-membrane structures. The authors suggested an increased rate of 
autophagy in the absence of STAT1 [261]. In line with these results, STAT1-deficient human 
fibrosarcoma cells exhibited increased autophagic activity [262].  
In contrast, another group proposed the role of STAT1 in the induction of autophagy. 
Formation of the autophagosome in the breast cancer cell line was STAT1-dependent [263] 
Fig. 4-14. Hypothesized role of STAT in Ang II-mediated end-organ damage. Activity of 
STAT1 is crucial for efficient expression of Cxcl9, Cxcl10 or Ccl2 upon Ang II infusion. 
Enhanced chemokine expression facilitates leukocyte trafficking and tissue injury. 
Additionally, STAT1 affects expression of iNOS and important components of NADPH 
oxidase, thus further contributing to ROS production. For details see text. 
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and IFNγ was found to induce cell autophagy [264, 265]. Taken together, these data imply  
a novel STAT1-dependent and tissue-specific role in the regulation of autophagy.  
Altogether, the results presented in this chapter provide experimental evidence for the 
function of STAT1 in Ang II-mediated tissue injury (Fig. 4-14). During Ang II infusion, activated 
STAT1 promotes expression of Ccl2, Cxcl10, Cxcl9 chemokines, thus leading to increased 
CD45+ infiltration. Activated leukocytes induce the oxidative burst, thus promoting damage 
and contributing to tissue fibrosis and organ malfunction. Additionally, the transcriptional 
activity of STAT1 in the vessel wall affects expression of iNOS and important components of 
NADPH oxidase, thus further contributing to ROS production. An increased oxidative burst 
limits the amount of bioavailable NO and causes endothelial dysfunction. In contrast to the 
vasculature lack of STAT1 in the kidney resulted in deterioration of the organ function.  
This phenotype occurred most likely due to the impaired autophagy mechanism after 
stimulation with Ang II.  
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Chapter 5 
STAT1 and IRFs in Cardiovascular disease 
 
Cardiovascular diseases are globally the leading cause of death. According to the World Health 
Organization, the number of people that will die from CVDs will increase to 23.3 million in 
2030 [1, 2]. In Poland, cardiovascular disorders are the reason for 46% of total deaths [266], 
and atherosclerosis accounts for 18% of those deaths. Therefore, a detailed understanding of 
the mechanisms contributing to the progression of this type of diseases together with 
prevention is a true challenge to the modern health care system. Recently, more attention has 
been paid to the role of the immune component in the progression of CVDs. Transcription 
factor STAT1 together with downstream-activated IRFs play a crucial role in regulating the 
immune response. In this chapter we further summarize the findings presented in the thesis 
and discuss potential applications as well as future research directions.  
 
STAT1-dependent signal integration between IFNγ and TLR4 in non-immune cells  
First, we studied the role of STAT1 and IRFs as potential regulators of inflammation in non-
immune cells. We hypothesized that STAT1- and IRF-mediated gene expression accelerates 
the inflammatory response which negatively affects the cardiovascular system. Indeed,  
the results presented in Chapter 2 and further extended in Chapter 3 showed that in addition 
to myeloid and lymphoid cells, STAT1 in the vascular cells together with downstream-
activated IRF1 and IRF8 orchestrate a platform for crosstalk between the JAK/STAT and TLR4 
pathway. In addition, we were able to, for the first time, identify IRF8 in cells from the 
vasculature. Interestingly, by analyzing expression profiles in non-immune cells we could 
distinguish cell type-specific regulatory mechanisms activating the IFNγ- and LPS-mediated 
response. In cells from the vasculature, synergistic amplification of the genes was dependent 
on an increased amount of phosphorylated STAT1 and its subsequent interaction with LPS-
activated transcription factors. In contrast to the ECs and VSMCs, we did not detect increased 
phosphorylation of STAT1 in stimulated proximal tubular cells. We postulated the mechanism 
in which not increased STAT1 activity but increased expression of STAT1-mediated 
transcription factors and subsequent interaction with NFκB facilitated signal integration of the 
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downstream genes. Indeed, expression of IRF1 was highly amplified upon treatment with 
IFNγ, but not upon LPS. These results indicated the involvement of IRF1 in the synergistic 
amplification of downstream genes in proximal tubular cells and emphasized tissue-specific 
mechanisms regulating signal integration. 
Although not fully understood, functional cooperation between STAT1 and IRF8 was observed 
in immune cells. IRF8 abundance was synergistically amplified upon treatment with IFNγ and 
LPS in macrophages [115]. Moreover, its expression and subsequent interaction with IRF1 was 
mandatory for Nos2 activation. IRF8-deficient macrophages stimulated with IFNγ did not 
produce nitrite [208, 267]. Our results pointed to STAT1-dependent expression and synergistic 
amplification of IRF8 in VSMCs and ECs. However, the precise role of IRF8 still has to be 
addressed. First, it is not known which genes are regulated by IRF8 in non-immune cells. Based 
on evidence in the literature, we studied the expression of Nos2 and Ccl5, although it is very 
likely that there are other IRF8-dependent genes. Microarray experiments combined with 
chromatin immunoprecipitation (ChIP) sequencing or ChIP-PCR performed on IRF8-deficient 
ECs and VSMCs should answer this question. Moreover, the precise mechanism by which IRF8 
contributes to gene expression upon signal integration is still not fully understood. Zhao et al. 
suggested that IRF8 promotes crosstalk between TLR and IFNγ signaling through interaction 
with crucial components of the TLR4 pathway [115]. Additionally, IRF8 was found to interact 
with other members of the TLR family such as TLR3 and TLR2, which have recently been 
recognized as playing a role in the cardiovascular system [268]. It would be interesting to 
verify whether a similar phenomenon occurs in the vascular cells and whether this mechanism 
is related to the activity of STAT1. Recently, IRF8 was proposed as playing a crucial role in 
regulating the induction of the M1 phenotype in macrophages [195]. These classically 
activated macrophages express a high level of pro-inflammatory cytokines and contribute  
to the progression of cardiovascular disease. Additionally, modification of IRF8 by small 
ubiquitin-like modifiers (SUMO) inhibits IRF8 action and, as a consequence, the macrophage 
phenotype switch that prevents expression of proinflammatory mediators such as IL12p40 
[269]. Since expression of IRF8 in ECs and VSMCs seems to be STAT1-dependent, it is tempting 
to suggest a mechanism where IRF8 may in part account for the “immune cell-specific” STAT1-
dependent functions of IFNγ. In this process the ECs and VSMCs change their phenotype and 
actively participate in amplifying and sustaining the inflammatory process. As such, IRF8 can 
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be considered as an interesting therapeutic target that modulates the STAT1-mediated 
proinflammatory response. 
 
STAT1 and IRFs in atherosclerosis and hypertension  
The results presented in Chapters 1 and 2 strongly suggest that STAT1 together with 
upregulated IRF1, IRF8 and the activated TLR4 pathway coordinate a platform for synergistic 
amplification of genes, which results in phenotypic changes of the vascular cells and leads to 
amplified pro-atherogenic responses. Thus, ECs and VSMCs can be considered not only as 
passive receivers of the immune-driven stimuli but also as active modulators of vessel 
damage. Increased activation of STAT1 and STAT1-dependent IRF1 and IRF8 (e.g. in the 
presence of JAK/STAT and TLR4 agonists) can be the reason for synergistic amplification of 
multiple chemokines, adhesion molecules and antiviral and antibacterial response proteins 
which, in turn, facilitate white blood cell trafficking and further contributes to the progression 
of cardiovascular disease such as atherosclerosis. Microarray analysis performed on 
stimulated VSMCs identified a whole set of STAT1-dependent genes that were prone to 
synergistic amplification. Promoter analysis predicted the presence of transcription binding 
sites containing GAS, ISRE or NFkB elements either alone or in different combinations. 
Moreover, immunohistochemistry performed on human specimens revealed the presence of 
phosphorylated STAT1 as well as STAT1-dependent genes in carotid plaque.  
 
Atherosclerosis is not the only immune-driven CVD disease. Recent data indicate that also in 
hypertension the immune system is an important contributor to its progression. In Chapter 4 
we studied the role of STAT1 in an Ang II-induced model of hypertension and tissue injury. 
Just as in the model of atherosclerosis, here too we could identify several STAT1 downstream 
genes that were upregulated upon treatment with Ang II, including genes involved in 
leukocyte trafficking and oxidative burst. Immunohistochemistry together with the analysis of 
vessel function confirmed the importance of STAT1 in regulating Ang II-mediated tissue 
damage. Based on our results we hypothesized that Ang II-increased leukocyte infiltration is at 
least partially mediated through the transcriptional activity of STAT1. Increased expression  
of chemokines resulted in increased CD45+ cell infiltration, accelerated oxidative burst and,  
88 | P a g e  
 
as such, contributed to tissue fibrosis and organ malfunction. Importantly, our in silico analysis 
predicted the presence of STAT- binding sites in the promoter region of genes involved in the 
regulation of oxidative stress. These results allow us to suggest that the action of STAT1 is not 
only limited to the induction of chemokine synthesis but can also actively participate in 
promoting tissue injury by stimulation of NADPH oxidase expression. Thus, due to its 
involvement in the regulation of ROS production, STAT1 might be considered as an interesting 
therapeutic target. This is particularly important in the context of CVDs, as ROS has been 
associated in the pathogenesis of many of them. Indeed, some studies have pointed to  
the role of the STAT family in regulating NADPH expression [226]. Johnson et al. showed that 
the inhibitors of STAT3 prevented Ang II-mediated oxidative stress and EC dysfunction [270]. 
Since all known inhibitors of the JAK/STAT pathway that block STAT3 also interfere with 
STAT1, these results suggest the involvement of STAT1 and STAT3 in the regulation of 
oxidative stress. Our in vivo studies together with promoter analysis support this hypothesis 
and open up a new and interesting research area.  
Interestingly, abolished expression of inflammatory genes and markers of fibrosis in the 
kidneys of STAT1-deficient animals did not improve organ function but surprisingly 
accelerated the injury. We observed increased albuminuria indicating enhanced Ang II-
induced glomerular damage in STAT1-deficient mice. Our findings indicate that systemic 
inhibition of factors that participate in inflammation in certain conditions may not be 
beneficial to organ function. Moreover, we proposed that disturbed autophagy was the 
reason for ameliorated organ damage in the absence of STAT1. However, how exactly STAT1 
modulates autophagy remains an open question. Further experiments with the use of tissue-
specific knockouts are mandatory to determine the role of STAT1 in this aspect. 
Similar to atherosclerosis, the role of the JAK/STAT pathway in obesity and obesity-related 
insulin resistance has been investigated. This is particularly important as obesity is associated 
with increased cardiovascular risk [271-273]. Compared with the control, animals fed a high-
fat diet had an increased amount of infiltrating Th1 cells and produced a higher amount of 
IFNγ. Obese IFNγ-deficient mice expressed less proinflammatory mediators such as Ccl2 or 
TNFα and had better glucose tolerance [274]. McGillicuddy et al. demonstrated that 
stimulation of adipocytes with IFNγ induces insulin resistance and ameliorates triglyceride 
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storage [275]. The authors suggested that JAK1 and STAT1 are crucial players of these events. 
Indeed, our preliminary studies suggested the role of STAT1 in the progression of insulin 
resistance. Genome-wide studies comparing the expression profiles of fat pads isolated from 
WT and STAT1-/- animals fed a high-fat diet revealed significant changes in the expression of 
genes involved in the glucose metabolism (data not shown). Nevertheless, it is not known how 
STAT1 modulates adipocyte functions and whether STAT1-mediated alterations contribute to 
vessel function. These issues will be the subject of further investigation.  
 
Besides STAT1, recent data indicate the involvement of proteins from the IRF family in the 
progression of cardiovascular disease. IRFs were found to be involved in the regulation of 
cardiac hypertrophy and remodeling in response to stress [276]. Expression of IRF7 was 
downregulated upon treatment with Ang II or phenylephrine in cardiomyocytes. In line with 
these results, in vivo studies performed on animals with disturbed IRF7 expression revealed 
the crucial role of IRF7 in the regulation of cardiac hypertrophy [277]. In this model, aortic 
constriction was performed and cardiac hypertrophy together with heart failure were 
investigated. Similarly to IRF7, IRF3 and IRF9 were protective against pressure overload-
induced hypertrophy. Interestingly, IRF8 has, on the one hand, been found to enhance smooth 
muscle cell proliferation and neointima formation but, on the other hand, IRF8 has also been 
evidenced to protect against cardiac hypertrophy and heart failure in a model of pressure 
overload [88, 278]. Expression of IRF1 was found to be altered in the tissue samples of 
patients with heart disease and in mice subjected to a model of pressure overload [279].  
Mice overexpressing IRF1 had increased ventricular dilation and fibrosis and dysfunction.  
Jiang et al. suggested that IRF1 participates in heart damage by direct activation of iNOS in 
response to stress conditions, thus further supporting the role of iNOS [279, 280]. Altogether, 
new evidence indicates the novel role of IRFs in the development of cardiovascular diseases. 
Yet their function is ambiguous; for example, it is still not known how IRFs are activated and 
whether their activation is interferon- and STAT-mediated. Therefore, further studies using 
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STAT1 and IRFs as therapeutic targets  
The data presented here but also data published by other groups suggest that STAT and IRF 
proteins can be considered as therapeutic targets affecting inflammatory processes during 
CVDs. Until now there have been no admitted drugs that specifically target STAT1 or IRF8. 
Besides STAT3, research on potential inhibitors of other STATs including STAT1 is very limited 
[281]. To the best of our knowledge there is no information on the modulators of IRF action.  
 
Several inhibition approaches that interfere with proteins from the STAT family have been 
suggested [281]. Among them we can distinguish strategies based on indirectly blocking STAT 
action, such as antibody-mediated prevention of pathway activation or inhibition of JAK 
kinases phosphorylation. Other strategies interfere with the binding of active STAT complexes 
to the promoters by applying decoy oligodeoxynucleotides, or they interfere with STAT mRNA 
using antisense oligonucleotides. Finally, the most common approach includes blocking the 
STAT SH2 domain and subsequent prevention of phosphorylation and dimer formation. 
Unfortunately, there are some pitfalls for such strategies. Targeting proteins upstream from 
STAT will result in interference of molecules that are not necessarily related to one pathway; 
for example, inhibition of JAK2 kinase phosphorylation with a compound such as AG490 will 
result in suppression of not only STAT1 but also STAT3. Inhibition of several targets at once 
may contribute to increased toxicity.  
Moreover, crystal structures are available only for a few members of the family, and as such 
quality models for virtual screening are poor [282]. STAT proteins share important structural 
similarities, and without detailed crystallography of human STAT (or their homologs), 
designing a specific STAT compound will be difficult. Indeed, our results showed that the 
inhibitors which were considered as specific toward STAT3 could also affect the activity of 
STAT1 and vice versa.  
Recently, our group presented a new strategy for the screening and validation of pre-selected 
STAT inhibitors [282]. Based on the available crystal models, we generated 3D structures for 
all human STATs. By using these models we could verify whether pre-selected compounds are 
specific to the targeted STAT or can associate with other proteins of the family. Following  
in silico comparative screening, we suggested cell-based multiple STAT activation in vitro 
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phosphorylation assay. This assay allows to verify the effect of the inhibitory compounds on 
the activity of STAT1 (constitutive or ligand-induced). 
Although targeting of STAT1 is an interesting research area, we might expect potential side 
effects due to the extensive regulatory features of STAT1. Fludarabine, the commercially 
available drug that is known to inhibit STAT1 action, is toxic [283]. Naturally, this could be 
explained by the reduced specificity of fludarabine to STAT1, but there is also other evidence 
indicating the potential risk of using STAT1 inhibitors. In the model of Ang II-induced 
abdominal aortic aneurysm, IFNγ-deficient mice had increased aneurysm incidence and death, 
although there was decreased atherosclerotic plaque formation [284]. In line with these 
results, Eagleton et al. noticed that loss of STAT1 was associated with higher incidence of 
aortic rupture [285]. In contrast, others noticed that mutation resulting in a gain of STAT1 
phosphorylation manifested aneurysm incidence [286]. Together with our results concerning 
kidney function as presented in Chapter 4, these studies postulate careful consideration in 
using the potential inhibitors of STAT1 and enforce a more specific approach. Importantly,  
our experiments suggest not only STAT1 but also IRFs as potential targets of novel drugs. 
Indeed, recent data presented in the subsection above seem to support the relevance of such 
an approach. Considering the structural similarities among proteins from the IRF family,  
we believe that the strategy proposed for STAT proteins can also be applied for IRFs.  
 
Diagnostic potential of STAT1 and IRFs  
A biomarker is defined as “a characteristic that is objectively measured and evaluated as  
an indicator of normal biological processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention” [287]. Biomarkers play a constantly increasing role in 
modern medicine. The Framingham Heart Study identified a whole set of traditional markers 
that are commonly accepted as predictors of cardiovascular disease. Among them we can 
distinguish age, gender, cigarette smoking, high blood pressure, elevated cholesterol levels, 
diabetes mellitus, obesity and familial history of coronary heart disease. However, there was 
no observable risk factor in 10-15% of patients who developed CVDs [288, 289]. On the 
contrary, some people with traditional risk factors do not develop CVDs. Moreover, classical 
risk factors are not optimal in reference to the efficacy assessment of new cardiovascular 
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drugs. In order to demonstrate the substantial benefit of a new therapeutic drug, clinical trials 
including large cohorts followed for many years have to be conducted. The lack of good 
biomarkers limits our ability to exclude potential therapeutics that do not meet the expected 
outcome at early stages of drug development.  
 
Table 5-1. Genes prone to signal integration are associated with CVDs.  
Genomatix software were used to assign 30 synergistically amplified genes listed in table 3-2  to 
the MeSH terms associated with diseases. 20 most relevant terms related to CVDs is presented.  
 




Tnfaip2, Gja4, Neurl3, Gbp5, Tnfrsf11a, Rsad2, Mx1, Ccl5, Nos2, Cxcl10,  




Tnfaip2, Gja4, Tnfrsf11a, Mx1, Ccl5, Nos2, Cxcl10, Irf8, Cd40, Has1, Cxcl9, 
Serpina3g, Atf3 
Inflammation 6,31E-09 
Tnfaip2, Gja4, Neurl3, Ccrl2, Gbp5, Tnfrsf11a, Rsad2, Mx1, Ccl5, Nos2, Cxcl10, 
Irf8, Cd40, Ccl12, Has1, Egr2, Ccl8, Cxcl9, Serpina3g, Cd74, Ubd, Atf3, Ifi205 
Atherosclerosis 4,24E-08 
Tnfaip2, Gja4, Tnfrsf11a, Mx1, Ccl5, Nos2, Cxcl10, Irf8, Cd40, Has1, Egr2, Ccl8, 
Cxcl9, Cd74, Atf3 
Fibrosis 1,92E-07 
Tnfaip2, Gja4, Tnfrsf11a, Mx1, Ccl5, Nos2, Cxcl10, Cd40, Ccl12, Has1, Egr2, 
Ccl8, Cxcl9, Cd74, Atf3 
Autoimmune Diseases 3,01E-07 
Tnfaip2, Gja4, Ccrl2, Tnfrsf11a, Rsad2, Mx1, Ccl5, Nos2, Cxcl10, Irf8, Cd40, 
Ccl12, Has1, Egr2, Ccl8, Cxcl9, Serpina3g, Cd74, Ubd, Atf3, Ifi205, Upp1 
Arteriosclerosis 1,01E-06 
Tnfaip2, Gja4, Tnfrsf11a, Mx1, Ccl5, Nos2, Cxcl10, Irf8, Cd40, Has1, Egr2, Ccl8, 
Cxcl9, Cd74, Atf3, Upp1 








Tnfaip2, Gja4, Tnfrsf11a, Mx1, Ccl5, Nos2, Cxcl10, Irf8, Cd40, Has1, Egr2, Ccl8, 
Cxcl9, Cd74, Atf3, Upp1 
Myocardial Infarction 5,82E-06 
Tnfaip2, Gja4, Tnfrsf11a, Ccl5, Nos2, Cxcl10, Cd40, Has1, Egr2, Ccl8, Cxcl9, 
Cd74, Atf3 
Myocarditis 8,65E-06 Tnfaip2, Tnfrsf11a, Ccl5, Nos2, Cxcl10, Cd40, Ccl12, Cxcl9 
Coronary Disease 2,32E-05 





Tnfaip2, Mx1, Ccl5, Nos2, Cxcl10, Cd40, Cxcl9 
Carotid Stenosis 2,63E-05 Tnfaip2, Gja4, Tnfrsf11a, Ccl5, Nos2, Cd40, Cd74 
Myocardial Ischemia 2,77E-05 
Tnfaip2, Gja4, Tnfrsf11a, Ccl5, Nos2, Cxcl10, Irf8, Cd40, Has1, Egr2, Ccl8, 
Cxcl9, Cd74, Ubd, Atf3 
Hypertension, Portal 2,84E-05 Tnfaip2, Gja4, Ccl5, Nos2, Cxcl10, Cxcl9 




Tnfrsf11a, Ccl5, Nos2, Cxcl10, Cd40, Cxcl9 
Hyperlipidemias 6,06E-05 Tnfaip2, Tnfrsf11a, Ccl5, Nos2, Cxcl10, Irf8, Cd40, Has1, Ccl8, Atf3 
 
As a consequence, there has been a dramatic increase in R&D costs and in the pharmaceutical 
industry’s shift of resources towards other research areas [290]. Thus, identifying new 
markers of clinical endpoints in CVDs is crucial for public health. Such new, validated 
biomarkers will help detect and monitor progression of the disease. Additionally, new 
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biomarkers will aid in quick identification of potential targets that are toxic or did not provide 
better clinical efficacy.  
 
Recent results obtained in our laboratory as well as data presented in this thesis suggest that 
sets of synergistically amplified STAT1-dependent genes can be considered as novel diagnostic 
markers of CVDs. Indeed, by using the Medical Subject Headings Database (MeSH) [291] we 
could observe a significant association between 30 investigated genes (Table 3-2) and 
cardiovascular diseases (Table 5-1). The results of the screening confirmed statistically 
significant enrichment of MeSH terms related to CVDs and pointed to the role of amplified 
genes in CVDs. Furthermore, we used two microarray datasets obtained from human coronary 
plaques and human carotid plaques (acc. no. GSE40231 and GSE21545, respectively [292, 
293]) and compared them with the 30 IFNγ- and LPS-amplified STAT1-target genes. Our data 
mining of the microarray studies obtained from human specimens identified 12 out of 30 
synergistically amplified genes to be expressed in carotid plaques and 6 out of 30 in coronary 
plaques (Table 5-2). 
 








CD74 +  
CCL5 + + 
CXCL10 + + 
GBP5 +  
IRF8 +  
CCL8 +  
CXCL9 + + 
CCRL2 +  
UBD +  
SECTM1 +  
IFI16 +  
UPP1 + + 
ATF3  + 
FAM26F  + 
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Additional studies from our group predicted potential STAT1 but also STAT1-NFκB and STAT1-
IRF modules in many of the genes expressed in these types of plaques [198]. These genes 
were involved in processes that are crucial for formation of the plaque, such as cell adhesion, 
migration, matrix remodeling and calcification. Importantly, many of the potentially STAT1-
dependent proteins are either membrane-bound or secreted, and as such can be detected in 
the serum [198]. Therefore, it is tempting to suggest a selection of these genes as markers of 
the onset of atherosclerosis. Studies with the multi-marker approach using the above 
identified STAT1-dependent genes may reveal a substantial clinical benefit. Although further 
research is needed to confirm our hypothesis, data provided by other groups seem to support 
it; for example, Harder et al. showed that in addition to traditional risk factors,  
13 inflammatory markers (including STAT1-dependent ones such as CXCL10, CCL2, CCL5) 
significantly improved the prediction of coronary events and type 2 diabetes [294]. Kharti et 
al. analyzed microarray studies from 236 graft biopsy samples from four different organs and 
identified 11 genes (e.g. CXCL10, CXCL9,) overexpressed in acute rejection [295].  
More importantly, they found that STAT1 and NFκB are central regulators of 10 identified 
genes and that their expression correlates with the degree of organ damage. Then they 
confirmed that STAT1- and NFκB-dependent genes are expressed in the animal model of the 
heart transplant and showed that treatment with atorvastatin reduces expression of these 
genes and as such is beneficial for allograft survival [295]. It is tempting to suggest a similar 
approach in studying the role of STAT1, IRFs and genes regulated by their activity in different 
models of CVDs.  
  




Taken together, our results provide further evidence for the crosstalk between IFNγ and TLR4 
in non-immune cells and indicate the central role of STAT1, activated IRF1 and IRF8 in the 
mechanism underlying expression of proinflammatory mediators. A genome-wide analysis in 
VSMCs identified a whole set of STAT1-dependent genes that were synergistically affected by 
interactions between IFNγ and TLR4. Among the highly amplified genes we could 
predominantly distinguish chemokines and adhesion molecules. Functional assays together 
with immunohistochemical stainings of phosphorylated STAT1 and STAT1-dependent genes 
confirmed the importance of STAT1 in the regulation of vascular inflammation. Moreover, 
analysis of STAT1 function in Ang II-induced hypertensive end organ damage further 
supported its role in the regulation of inflammation and vessel function. These data provide 
new insight into understanding the role of STAT1-driven inflammatory processes which,  
in turn, play a crucial role in the pathophysiology of CVDs. 
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Streszczenie w języku polskim 
 
Najnowsze badania z zakresu etiologii chorób układu krążenia wskazują na negatywną rolę 
układu immunologicznego. W specyficznych warunkach środowiskowych ściśle powiązanych 
ze stylem życia, układ immunologiczny może przyczyniać się do rozwoju takich chorób jak 
miażdżyca czy nadciśnienie tętnicze. Wraz z aktywacją systemu odporności dochodzi do 
uszkodzenia śródbłonka, co z kolei skutkuje osłabieniem zdolność regulowania wazodylatacji. 
Dysfunkcja komórek budujących naczynia krwionośne związana jest również z ekspresją 
substancji prozapalnych (m.in. chemokin, cytokin i cząsteczek adhezyjnych), które umożliwiają 
migrację oraz adhezję komórek układu immunologicznego do ściany naczynia. 
Istotną rolę w regulacji procesów zapalnych odgrywa interferon gamma (IFNγ) oraz czynniki 
wpływające na receptor Toll-podobny 4 (TLR4). IFNγ stymuluje szlak sygnałowy JAK/STAT 
poprzez aktywację czynnika transkrypcyjnego STAT1 oraz czynników transkrypcyjnych 
regulowanych interferonem (IRF). Doświadczenia przeprowadzone na komórkach układu 
immunologicznego wykazały, że zarówno szlak przekazywania sygnału JAK/STAT, jak i TLR4 
współdziałają ze sobą za pośrednictwem białek STAT1 oraz białek z rodziny IRF. Eksperymenty 
przedstawione w tej pracy miały na celu zweryfikowanie funkcji czynnika transkrypcyjnego 
STAT1 oraz IRF w integracji szlaków sygnalizacyjnych IFNγ i receptora TLR4 w aktywacji 
procesów zapalnych związanych z chorobami układu krążenia.  
Nasza hipoteza zakładała, że w komórkach nienależących do układu immunologicznego, takich 
jak komórki śródbłonka oraz mięśni gładkich, integracja szlaków sygnalizacyjnych JAK/STAT 
oraz TLR4 za pośrednictwem STAT1 oraz IRF prowadzi do synergistycznego wzrostu ekspresji 
białek zaangażowanych w proces zapalny. W pierwszym rozdziale podsumowano aktualną 
wiedzę na temat szlaków sygnalizacyjnych JAK/STAT, TLR4 oraz czynników transkrypcyjnych 
STAT1 oraz IRF ze szczególnym uwzględnieniu ich roli w chorobach układu krążenia. Rozdział 
drugi zawiera serię eksperymentów na komórkach śródbłonka, mięśni gładkich oraz komórek 
budujących kanaliki nerkowe, które udowadniają istnienie integracji szlaków sygnalizacyjnych 
JAK/STAT oraz TLR4 za pośrednictwem STAT1 oraz IRF. Eksperymenty omówione w trzecim 
rozdziale nie tylko identyfikują grupy genów podatnych na integrację wyżej wymienionych 
szlaków sygnalizacyjnych, ale również dostarczają dowodów na jej funkcjonalne znaczenie w 
patogenezie chorób układu krążenia. Ponadto rozdział ten opisuje nowo zidentyfikowany 
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czynnik transkrypcyjny IRF8 oraz wskazuje jego potencjalną rolę. W kolejnej części 
weryfikowana jest funkcja STAT1 w modelu nadciśnienia indukowanego angiotensyną II. 
Poprzez analizę eksperymentów wykonanych na zwierzętach pozbawionych genu STAT1 
wykazano istotną funkcję białka STAT1 w mechanizmie ekspresji genów związanych z 
procesem zapalnym oraz białek uczestniczących w indukcji stresu oksydacyjnego. W ostatnim 
rozdziale podsumowane zostały wyniki doświadczeń oraz przeanalizowane wady i zalety 
potencjalnych możliwości zastosowania związków wpływających na aktywność STAT1 oraz 
potencjalne zastosowanie w diagnostyce chorób układu krążenia.  
 
Badania przeprowadzone w tej pracy poszerzyły wiedze z zakresu etiologii chorób układu 
krążenia takich jak miażdżyca i nadciśnienie tętnicze. Wykonane eksperymenty potwierdziły 
istnienie mechanizmu kooperacji pomiędzy szlakiem JAK/STAT i TLR4 w komórkach 
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